<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
	<channel rdf:about="http://www.mdpi.com/rss/section/molecular_pathology">
		<title>IJMS: Molecular Pathology</title>
		<link>http://www.mdpi.com/section/molecular_pathology</link>
		<description>In this IJMS section, original peer-reviewed papers from all aspects of molecular pathology are published. Studies on cellular and molecular mechanisms of disease which report important findings on disease pathogenesis or basic biological mechanisms that relate to disease will be considered. We welcome  studies on human disease and relevant experimental models using cellular, molecular, biological, chemical and immunological approaches in conjunction with morphology.</description>
								<items>
			<rdf:Seq>
							<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/13/2/1886/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/13/2/1632/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/13/2/1461/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/12/9369/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/12/9277/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/12/8333/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/11/8275/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/11/8133/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/11/7635/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/11/7554/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/11/7424/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/10/6781/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/10/6645/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/9/5844/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/9/5461/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/8/5052/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/5/3055/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/4/2477/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/3/1595/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/3/1533/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/2/1334/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/2/1306/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/2/1222/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/2/1133/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/2/1009/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/2/983/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/2/971/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/1/773/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/1/694/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/1/668/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/1/613/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/1/506/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/12/1/410/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/12/5120/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/11/4580/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/11/4465/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/11/4441/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/10/3999/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/10/3748/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/9/3513/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/8/2901/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/8/2875/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/7/2658/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/6/2306/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/6/2291/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/5/2109/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/5/2039/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/4/1253/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/2/544/" />
            				<rdf:li rdf:resource="http://www.mdpi.com/1422-0067/11/1/312/" />
                    	</rdf:Seq>
		</items>
				<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
	</channel>
	<item rdf:about="http://www.mdpi.com/1422-0067/13/2/1886/">
	<title>IJMS, Vol. 13, Pages 1886-1918: The mTOR Signalling Pathway in Human Cancer</title>
	<link>http://www.mdpi.com/1422-0067/13/2/1886/</link>
	<description>The conserved serine/threonine kinase mTOR (the mammalian target of rapamycin), a downstream effector of the PI3K/AKT pathway, forms two distinct multiprotein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to rapamycin, activates S6K1 and 4EBP1, which are involved in mRNA translation. It is activated by diverse stimuli, such as growth factors, nutrients, energy and stress signals, and essential signalling pathways, such as PI3K, MAPK and AMPK, in order to control cell growth, proliferation and survival. mTORC2 is considered resistant to rapamycin and is generally insensitive to nutrients and energy signals. It activates PKC-α and AKT and regulates the actin cytoskeleton. Deregulation of multiple elements of the mTOR pathway (PI3K amplification/mutation, PTEN loss of function, AKT overexpression, and S6K1, 4EBP1 and eIF4E overexpression) has been reported in many types of cancers, particularly in melanoma, where alterations in major components of the mTOR pathway were reported to have significant effects on tumour progression. Therefore, mTOR is an appealing therapeutic target and mTOR inhibitors, including the rapamycin analogues deforolimus, everolimus and temsirolimus, are submitted to clinical trials for treating multiple cancers, alone or in combination with inhibitors of other pathways. Importantly, temsirolimus and everolimus were recently approved by the FDA for the treatment of renal cell carcinoma, PNET and giant cell astrocytoma. Small molecules that inhibit mTOR kinase activity and dual PI3K-mTOR inhibitors are also being developed. In this review, we aim to survey relevant research, the molecular mechanisms of signalling, including upstream activation and downstream effectors, and the role of mTOR in cancer, mainly in melanoma.</description>
	
	<guid>http://www.mdpi.com/1422-0067/13/2/1886/</guid>
	<pubDate>Fri, 10 Feb 2012 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2012-02-10</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>1886</prism:startingPage>
		<prism:endingPage>1918</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>The mTOR Signalling Pathway in Human Cancer</dc:title>
	<dc:date>2012-02-10</dc:date>
	<dc:identifier>doi: 10.3390/ijms13021886</dc:identifier>
		<dc:creator>Helena Pópulo</dc:creator>
		<dc:creator>José Manuel Lopes</dc:creator>
		<dc:creator>Paula Soares</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/13/2/1632/">
	<title>IJMS, Vol. 13, Pages 1632-1643: Analysis of Snail-1, E-Cadherin and Claudin-1 Expression in Colorectal Adenomas and Carcinomas</title>
	<link>http://www.mdpi.com/1422-0067/13/2/1632/</link>
	<description>We report the expression of Snail-1, E-cadherin and claudin-1 by indirect immunohistochemistry in colonic neoplasia. Snail-1 is a zinc finger transcription factor expressed in cells that already have undergone almost complete epithelial-mesenchymal transition (EMT) and have already evaded from the tumor. The main mechanism by which Snail induces EMT is downregulation of E-cadherin, of which expression was shown to be frequently downregulated in many different types of tumors, where it accompanies the invasiveness and metastatic behavior of malignant cells. Moreover, Snail-1 may downregulate the expression of claudin-1, a cell-cell adhesion protein which plays a likely role in progression and dissemination during tumorigenesis. Snail-1 was expressed in both carcinoma and adenoma cells with histologically normal epithelium in the mucosa, adjacent to the tumors, without significant differences, and predominant strong intensity of staining. Statistically significant differences were revealed between normal and tumorous epithelium (p = 0.003) at the subcellular level, where the shift of the protein to the cytoplasm with combined cytoplasmic/nuclear or pure cytoplasmic expression was observed. E-cadherin expression was present in 100% of cases of both adenocarcinomas and adenomas, with prevailing strong membranous immunoreactivity and no differences between protein expression in tumors and normal mucosa. Predominating strong positivity of claudin-1 was detected in tumor cells of adenocarcinomas and adenomas. Marked differences were seen in protein localization, where membranous staining, typical for nontumorous epithelium, changed to combined membranous/cytoplasmic expression in adenocarcinomas (p = 0.0001) and adenomas (0.0002), in which cytoplasmic shift was associated with a higher degree of dysplasia. Furthermore, membranous/cytoplasmic localization was more frequent in the carcinoma group (87%) in comparison with adenomas (51%) (p = 0.0001). We conclude that dystopic subcellular localizations of Snail-1 and claudin-1 may participate in changes of cellular morphology and behavior which might be associated with altered effectory pathways of proteins and thus substantially contribute to the cancer development.</description>
	
	<guid>http://www.mdpi.com/1422-0067/13/2/1632/</guid>
	<pubDate>Thu, 02 Feb 2012 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2012-02-02</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1632</prism:startingPage>
		<prism:endingPage>1643</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Analysis of Snail-1, E-Cadherin and Claudin-1 Expression in Colorectal Adenomas and Carcinomas</dc:title>
	<dc:date>2012-02-02</dc:date>
	<dc:identifier>doi: 10.3390/ijms13021632</dc:identifier>
		<dc:creator>Michala Bezdekova</dc:creator>
		<dc:creator>Svetlana Brychtova</dc:creator>
		<dc:creator>Eva Sedlakova</dc:creator>
		<dc:creator>Katerina Langova</dc:creator>
		<dc:creator>Tomas Brychta</dc:creator>
		<dc:creator>Kamil Belej</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/13/2/1461/">
	<title>IJMS, Vol. 13, Pages 1461-1480: Nanoscopic and Photonic Ultrastructural Characterization of Two Distinct Insulin Amyloid States</title>
	<link>http://www.mdpi.com/1422-0067/13/2/1461/</link>
	<description>Two different conformational isoforms or amyloid strains of insulin with different cytotoxic capacity have been described previously. Herein these filamentous and fibrillar amyloid states of insulin were investigated using biophysical and spectroscopic techniques in combination with luminescent conjugated oligothiophenes (LCO). This new class of fluorescent probes has a well defined molecular structure with a distinct number of thiophene units that can adopt different dihedral angles depending on its binding site to an amyloid structure. Based on data from surface charge, hydrophobicity, fluorescence spectroscopy and imaging, along with atomic force microscopy (AFM), we deduce the ultrastructure and fluorescent properties of LCO stained insulin fibrils and filaments. Combined total internal reflection fluorescence microscopy (TIRFM) and AFM revealed rigid linear fibrous assemblies of fibrils whereas filaments showed a short curvilinear morphology which assemble into cloudy deposits. All studied LCOs bound to the filaments afforded more blue-shifted excitation and emission spectra in contrast to those corresponding to the fibril indicating a different LCO binding site, which was also supported by less efficient hydrophobic probe binding. Taken together, the multi-tool approach used here indicates the power of ultrastructure identification applying AFM together with LCO fluorescence interrogation, including TIRFM, to resolve structural differences between amyloid states.</description>
	
	<guid>http://www.mdpi.com/1422-0067/13/2/1461/</guid>
	<pubDate>Wed, 01 Feb 2012 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2012-02-01</prism:publicationDate>
	<prism:volume>13</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1461</prism:startingPage>
		<prism:endingPage>1480</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Nanoscopic and Photonic Ultrastructural Characterization of Two Distinct Insulin Amyloid States</dc:title>
	<dc:date>2012-02-01</dc:date>
	<dc:identifier>doi: 10.3390/ijms13021461</dc:identifier>
		<dc:creator>Katarzyna Maria Psonka-Antonczyk</dc:creator>
		<dc:creator>Julien Duboisset</dc:creator>
		<dc:creator>Bjørn Torger Stokke</dc:creator>
		<dc:creator>Tamotsu Zako</dc:creator>
		<dc:creator>Takahiro Kobayashi</dc:creator>
		<dc:creator>Mizuo Maeda</dc:creator>
		<dc:creator>Sofie Nyström</dc:creator>
		<dc:creator>Jeff Mason</dc:creator>
		<dc:creator>Per Hammarström</dc:creator>
		<dc:creator>K. Peter R. Nilsson</dc:creator>
		<dc:creator>Mikael Lindgren</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/12/9369/">
	<title>IJMS, Vol. 12, Pages 9369-9388: Monitoring Insulin Aggregation via Capillary Electrophoresis</title>
	<link>http://www.mdpi.com/1422-0067/12/12/9369/</link>
	<description>Early stages of insulin aggregation, which involve the transient formation of oligomeric aggregates, are an important aspect in the progression of Type II diabetes and in the quality control of pharmaceutical insulin production. This study is the first to utilize capillary electrophoresis (CE) with ultraviolet (UV) detection to monitor insulin oligomer formation at pH 8.0 and physiological ionic strength. The lag time to formation of the first detected species in the aggregation process was evaluated by UV-CE and thioflavin T (ThT) binding for salt concentrations from 100 mM to 250 mM. UV-CE had a significantly shorter (5–8 h) lag time than ThT binding (15–19 h). In addition, the lag time to detection of the first aggregated species via UV-CE was unaffected by salt concentration, while a trend toward an increased lag time with increased salt concentration was observed with ThT binding. This result indicates that solution ionic strength impacts early stages of aggregation and β-sheet aggregate formation differently. To observe whether CE may be applied for the analysis of biological samples containing low insulin concentrations, the limit of detection using UV and laser induced fluorescence (LIF) detection modes was determined. The limit of detection using LIF-CE, 48.4 pM, was lower than the physiological insulin concentration, verifying the utility of this technique for monitoring biological samples. LIF-CE was subsequently used to analyze the time course for fluorescein isothiocyanate (FITC)-labeled insulin oligomer formation. This study is the first to report that the FITC label prevented incorporation of insulin into oligomers, cautioning against the use of this fluorescent label as a tag for following early stages of insulin aggregation.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/12/9369/</guid>
	<pubDate>Wed, 14 Dec 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-12-14</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>12</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>9369</prism:startingPage>
		<prism:endingPage>9388</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Monitoring Insulin Aggregation via Capillary Electrophoresis</dc:title>
	<dc:date>2011-12-14</dc:date>
	<dc:identifier>doi: 10.3390/ijms12129369</dc:identifier>
		<dc:creator>Elizabeth Pryor</dc:creator>
		<dc:creator>Joseph A. Kotarek</dc:creator>
		<dc:creator>Melissa A. Moss</dc:creator>
		<dc:creator>Christa N. Hestekin</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/12/9277/">
	<title>IJMS, Vol. 12, Pages 9277-9295: The Slowly Aggregating Salmon Calcitonin: A Useful Tool for the Study of the Amyloid Oligomers Structure and Activity</title>
	<link>http://www.mdpi.com/1422-0067/12/12/9277/</link>
	<description>Amyloid proteins of different aminoacidic composition share the tendency to misfold and aggregate in a similar way, following common aggregation steps. The process includes the formation of dimers, trimers, and low molecular weight prefibrillar oligomers, characterized by the typical morphology of globules less than 10 nm diameter. The globules spontaneously form linear or annular structures and, eventually, mature fibers. The rate of this process depends on characteristics intrinsic to the different proteins and to environmental conditions (i.e., pH, ionic strength, solvent composition, temperature). In the case of neurodegenerative diseases, it is now generally agreed that the pathogenic aggregates are not the mature fibrils, but the intermediate, soluble oligomers. However, the molecular mechanism by which these oligomers trigger neuronal damage is still unclear. Inparticular, it is not clear if there is a peculiar structure at the basis of the neurotoxic effect and how this structure interacts with neurons. This review will focus on the results we obtained using salmon Calcitonin, an amyloid protein characterized by a very slow aggregation rate, which allowed us to closely monitor the aggregation process. We used it as a tool to investigate the characteristics of amyloid oligomers formation and their interactions with neuronal cells. Our results indicate that small globules of about 6 nm could be the responsible for the neurotoxic effects. Moreover, our data suggest that the rich content in lipid rafts of neuronal cell plasma membrane may render neurons particularly vulnerable to the amyloid protein toxic effect.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/12/9277/</guid>
	<pubDate>Tue, 13 Dec 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-12-13</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>12</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>9277</prism:startingPage>
		<prism:endingPage>9295</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>The Slowly Aggregating Salmon Calcitonin: A Useful Tool for the Study of the Amyloid Oligomers Structure and Activity</dc:title>
	<dc:date>2011-12-13</dc:date>
	<dc:identifier>doi: 10.3390/ijms12129277</dc:identifier>
		<dc:creator>Marco Diociaiuti</dc:creator>
		<dc:creator>Maria Cristina Gaudiano</dc:creator>
		<dc:creator>Fiorella Malchiodi-Albedi</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/12/8333/">
	<title>IJMS, Vol. 12, Pages 8333-8346: Inhibition of Extracellular Signal-Regulated Kinases Ameliorates Hypertension-Induced Renal Vascular Remodeling in Rat Models</title>
	<link>http://www.mdpi.com/1422-0067/12/12/8333/</link>
	<description>The aim of this study is to investigate the effect of the extracellular signal-regulated kinases 1/2 (ERK1/2) inhibitor, PD98059, on high blood pressure and related vascular changes. Blood pressure was recorded, thicknesses of renal small artery walls were measured and ERK1/2 immunoreactivity and erk2 mRNA in renal vascular smooth muscle cells (VSMCs) and endothelial cells were detected by immunohistochemistry and in situ hybridization in normotensive wistar kyoto (WKY) rats, spontaneously hypertensive rats (SHR) and PD98059-treated SHR. Compared with normo-tensive WKY rats, SHR developed hypertension at 8 weeks of age, thickened renal small artery wall and asymmetric arrangement of VSMCs at 16 and 24 weeks of age. Phospho-ERK1/2 immunoreactivity and erk2 mRNA expression levels were increased in VSMCs and endothelial cells of the renal small arteries in the SHR. Treating SHR with PD98059 reduced the spontaneous hypertension-induced vascular wall thickening. This effect was associated with suppressions of erk2 mRNA expression and ERK1/2 phosphorylation in VSMCs and endothelial cells of the renal small arteries. It is concluded that inhibition of ERK1/2 ameliorates hypertension induced vascular remodeling in renal small arteries.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/12/8333/</guid>
	<pubDate>Mon, 28 Nov 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-11-28</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>12</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>8333</prism:startingPage>
		<prism:endingPage>8346</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Inhibition of Extracellular Signal-Regulated Kinases Ameliorates Hypertension-Induced Renal Vascular Remodeling in Rat Models</dc:title>
	<dc:date>2011-11-28</dc:date>
	<dc:identifier>doi: 10.3390/ijms12128333</dc:identifier>
		<dc:creator>Li Jing</dc:creator>
		<dc:creator>Jianzhong Zhang</dc:creator>
		<dc:creator>Jinping Sun</dc:creator>
		<dc:creator>Fengying Guo</dc:creator>
		<dc:creator>Xin An</dc:creator>
		<dc:creator>Kan Yang</dc:creator>
		<dc:creator>Ping Andy Li</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/11/8275/">
	<title>IJMS, Vol. 12, Pages 8275-8287: Active Protein Aggregates Produced in Escherichia coli</title>
	<link>http://www.mdpi.com/1422-0067/12/11/8275/</link>
	<description>Since recombinant proteins are widely used in industry and in research, the need for their low-cost production is increasing. Escherichia coli is one of the best known and most often used host organisms for economical protein production. However, upon over-expression, protein aggregates called inclusion bodies (IBs) are often formed. Until recently IBs formation represented a bottleneck in protein production as they were considered as deposits of inactive proteins. However, recent studies show that by choosing the appropriate host strain and designing an optimal production process, IBs composed from properly folded and biologically active recombinant proteins can be prepared. Such active protein particles can be further used for the isolation of pure proteins or as whole active protein particles in various biomedical and other applications. Therefore interest in understanding the mechanisms of their formation as well as their properties is increasing.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/11/8275/</guid>
	<pubDate>Tue, 22 Nov 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-11-22</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>8275</prism:startingPage>
		<prism:endingPage>8287</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Active Protein Aggregates Produced in Escherichia coli</dc:title>
	<dc:date>2011-11-22</dc:date>
	<dc:identifier>doi: 10.3390/ijms12118275</dc:identifier>
		<dc:creator>Špela Peternel</dc:creator>
		<dc:creator>Radovan Komel</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/11/8133/">
	<title>IJMS, Vol. 12, Pages 8133-8145: C57BL/KsJ-db/db-ApcMin/+ Mice Exhibit an Increased Incidence of Intestinal Neoplasms</title>
	<link>http://www.mdpi.com/1422-0067/12/11/8133/</link>
	<description>The numbers of obese people and diabetic patients are ever increasing. Obesity and diabetes are high-risk conditions for chronic diseases, including certain types of cancer, such as colorectal cancer (CRC). The aim of this study was to develop a novel animal model in order to clarify the pathobiology of CRC development in obese and diabetic patients. We developed an animal model of obesity and colorectal cancer by breeding the C57BL/KsJ-db/db (db/db) mouse, an animal model of obesity and type II diabetes, and the C57BL/6J-ApcMin/+ (Min/+) mouse, a model of familial adenomatous polyposis. At 15 weeks of age, the N9 backcross generation of C57BL/KsJ-db/db-ApcMin/+ (db/db-Min/+) mice developed an increased incidence and multiplicity of adenomas in the intestinal tract when compared to the db/m-Min/+ and m/m-Min/+ mice. Blood biochemical profile showed significant increases in insulin (8.3-fold to 11.7-fold), cholesterol (1.2-fold to 1.7-fold), and triglyceride (1.2-fold to 1.3-fold) in the db/db-Min/+ mice, when compared to those of the db/m-Min/+ and m/m-Min/+ mice. Increases (1.4-fold to 2.6-fold) in RNA levels of insulin-like growth factor (IGF)-1, IRF-1R, and IGF-2 were also observed in the db/db-Min/+ mice. These results suggested that the IGFs, as well as hyperlipidemia and hyperinsulinemia, promoted adenoma formation in the db/db-Min/+ mice. Our results thus suggested that the db/db-Min/+ mice should be invaluable for studies on the pathogenesis of CRC in obese and diabetes patients and the therapy and prevention of CRC in these patients.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/11/8133/</guid>
	<pubDate>Fri, 18 Nov 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-11-18</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>8133</prism:startingPage>
		<prism:endingPage>8145</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>C57BL/KsJ-db/db-ApcMin/+ Mice Exhibit an Increased Incidence of Intestinal Neoplasms</dc:title>
	<dc:date>2011-11-18</dc:date>
	<dc:identifier>doi: 10.3390/ijms12118133</dc:identifier>
		<dc:creator>Kazuya Hata</dc:creator>
		<dc:creator>Masaya Kubota</dc:creator>
		<dc:creator>Masahito Shimizu</dc:creator>
		<dc:creator>Hisataka Moriwaki</dc:creator>
		<dc:creator>Toshiya Kuno</dc:creator>
		<dc:creator>Takuji Tanaka</dc:creator>
		<dc:creator>Akira Hara</dc:creator>
		<dc:creator>Yoshinobu Hirose</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/11/7635/">
	<title>IJMS, Vol. 12, Pages 7635-7651: A 1HNMR-Based Metabonomics Study of Postmenopausal Osteoporosis and Intervention Effects of Er-Xian Decoction in Ovariectomized Rats</title>
	<link>http://www.mdpi.com/1422-0067/12/11/7635/</link>
	<description>A metabonomics method using 1H nuclear magnetic resonance spectroscopy (1HNMR) was applied to obtain a systematic view of the development and progression of postmenopausal osteoporosis. Using partial least squares discriminant analysis (PLS-DA), 26 and 34 characteristic resonances were found respectively in urine and plasma of ovariectomized rats (Variable importance, VIP value ≥1.0), and the significant altered metabolites identified in the plasma and urine were 10 and 9, respectively. Changes in these metabolites were related to the pathways of lipid, energy and amino acid metabolism, some of which involved the oxidative system. The described method was also used to analyze the therapeutic effects of Er-Xian Decoction (EXD), a traditional Chinese medicine widely used in the clinical treatment of osteoporosis in China. The results showed that EXD administration could provide satisfactory effects on osteoporosis through partially regulating the perturbed pathways of lipid, energy and amino acid metabolism and improving the anti-oxidative ability.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/11/7635/</guid>
	<pubDate>Tue, 08 Nov 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-11-08</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>7635</prism:startingPage>
		<prism:endingPage>7651</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>A 1HNMR-Based Metabonomics Study of Postmenopausal Osteoporosis and Intervention Effects of Er-Xian Decoction in Ovariectomized Rats</dc:title>
	<dc:date>2011-11-08</dc:date>
	<dc:identifier>doi: 10.3390/ijms12117635</dc:identifier>
		<dc:creator>Liming Xue</dc:creator>
		<dc:creator>Yin Wang</dc:creator>
		<dc:creator>Lei Liu</dc:creator>
		<dc:creator>Lu Zhao</dc:creator>
		<dc:creator>Ting Han</dc:creator>
		<dc:creator>Qiaoyan Zhang</dc:creator>
		<dc:creator>Luping Qin</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/11/7554/">
	<title>IJMS, Vol. 12, Pages 7554-7568: Enhanced Differentiation of Three-Gene-Reprogrammed Induced Pluripotent Stem Cells into Adipocytes via Adenoviral-Mediated PGC-1α Overexpression</title>
	<link>http://www.mdpi.com/1422-0067/12/11/7554/</link>
	<description>Induced pluripotent stem cells formed by the introduction of only three factors, Oct4/Sox2/Klf4 (3-gene iPSCs), may provide a safer option for stem cell-based therapy than iPSCs conventionally introduced with four-gene iPSCs. Peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) plays an important role during brown fat development. However, the potential roles of PGC-1α in regulating mitochondrial biogenesis and the differentiation of iPSCs are still unclear. Here, we investigated the effects of adenovirus-mediated PGC-1α overexpression in 3-gene iPSCs. PGC-1α overexpression resulted in increased mitochondrial mass, reactive oxygen species production, and oxygen consumption. Microarray-based bioinformatics showed that the gene expression pattern of PGC-1α-overexpressing 3-gene iPSCs resembled the expression pattern observed in adipocytes. Furthermore, PGC-1α overexpression enhanced adipogenic differentiation and the expression of several brown fat markers, including uncoupling protein-1, cytochrome C, and nuclear respiratory factor-1, whereas it inhibited the expression of the white fat marker uncoupling protein-2. Furthermore, PGC-1α overexpression significantly suppressed osteogenic differentiation. These data demonstrate that PGC-1α directs the differentiation of 3-gene iPSCs into adipocyte-like cells with features of brown fat cells. This may provide a therapeutic strategy for the treatment of mitochondrial disorders and obesity.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/11/7554/</guid>
	<pubDate>Mon, 07 Nov 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-11-07</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>7554</prism:startingPage>
		<prism:endingPage>7568</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Enhanced Differentiation of Three-Gene-Reprogrammed Induced Pluripotent Stem Cells into Adipocytes via Adenoviral-Mediated PGC-1α Overexpression</dc:title>
	<dc:date>2011-11-07</dc:date>
	<dc:identifier>doi: 10.3390/ijms12117554</dc:identifier>
		<dc:creator>Pin-I Huang</dc:creator>
		<dc:creator>Yueh-Ching Chou</dc:creator>
		<dc:creator>Yuh-Lih Chang</dc:creator>
		<dc:creator>Yueh Chien</dc:creator>
		<dc:creator>Kuan-Hsuan Chen</dc:creator>
		<dc:creator>Wen-Shin Song</dc:creator>
		<dc:creator>Chi-Hsien Peng</dc:creator>
		<dc:creator>Chin-Hong Chang</dc:creator>
		<dc:creator>Shin-Da Lee</dc:creator>
		<dc:creator>Kai-Hsi Lu</dc:creator>
		<dc:creator>Yi-Jen Chen</dc:creator>
		<dc:creator>Chia-Hua Kuo</dc:creator>
		<dc:creator>Chuan-Chih Hsu</dc:creator>
		<dc:creator>Hsin-Chen Lee</dc:creator>
		<dc:creator>Ming-Chi Yung</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/11/7424/">
	<title>IJMS, Vol. 12, Pages 7424-7437: Distribution and Clinical Significance of Th17 Cells in the Tumor Microenvironment and Peripheral Blood of Pancreatic Cancer Patients</title>
	<link>http://www.mdpi.com/1422-0067/12/11/7424/</link>
	<description>This study was designed to investigate the distribution of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients, its clinical significance, and the expression profile of Th17 cell-associated cytokines. The percentage of Th17 cells detected by flow cytometry analysis (FACS) was significantly higher in 46 pancreatic tumor tissues (5.28 ± 1.65%) compared with corresponding adjacent normal tissues (2.57 ± 0.83%) (P = 0.031). In addition, the percentage of Th17 cells was significantly higher in stage III-IV tumors than stage I-II tumors (P = 0.039). The percentage of Th17 cells in peripheral blood of 20 pancreatic cancer patients (3.99 ± 1.15%) was significantly higher than 15 healthy volunteers (1.98 ± 0.57%) (P = 0.027). Immunohistochemistry (IHC) was performed to detect IL-17+ cells in 46 pancreatic tumor tissues, as well as expression of CD34 in 24 tumor tissues. IL-17 was shown to mainly locate in cytoplasm, and the frequency of IL-17+ cells in tumor tissues (39/46) was higher than control (29/46). The presence of IL-17+ cells in tumor tissues was associated with tumor, node, and metastasis (TNM) stage, and lymph node metastasis (P = 0.012 and P = 0.009) but not with patient sex, age, tumor size, and histological grade (P &gt; 0.05). Interestingly, distribution of Th17 cells in tumor tissues was positively correlated with microvessel density (MVD) (r = 0.86, P = 0.018). Furthermore, the median survival time of patients with high and low level of IL-17+ cells frequency was 14.5 and 18.5 months respectively (P = 0.023). The serum levels of Th17 cell-associated cytokines, IL-17 and IL-23 in 20 pancreatic patients detected by enzyme-linked immunosorbent assay (ELISA) were 69.2 ± 28.5 pg/mL and 266.5 ± 98.1 pg/mL, respectively, which were significantly higher than 15 healthy volunteers (P = 0.015 and P = 0.02). Moreover, levels of IL-17 and IL-23 were significantly higher in stage III-IV tumors than stage I-II tumors (P = 0.04 and P = 0.036). This study suggests that increase in Th17 cells frequency and its related cytokines levels in pancreatic tumor tissues may indicate involvement in the invasion and metastasis of pancreatic cancer, which may thereby affect patient prognosis. Therefore, Th17 cells and related cytokines may be served as important immune indicators for predicting the prognosis of pancreatic cancer patients.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/11/7424/</guid>
	<pubDate>Fri, 28 Oct 2011 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-10-28</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>7424</prism:startingPage>
		<prism:endingPage>7437</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Distribution and Clinical Significance of Th17 Cells in the Tumor Microenvironment and Peripheral Blood of Pancreatic Cancer Patients</dc:title>
	<dc:date>2011-10-28</dc:date>
	<dc:identifier>doi: 10.3390/ijms12117424</dc:identifier>
		<dc:creator>Songbing He</dc:creator>
		<dc:creator>Min Fei</dc:creator>
		<dc:creator>Yugang Wu</dc:creator>
		<dc:creator>Dingcheng Zheng</dc:creator>
		<dc:creator>Daiwei Wan</dc:creator>
		<dc:creator>Liang Wang</dc:creator>
		<dc:creator>Dechun Li</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/10/6781/">
	<title>IJMS, Vol. 12, Pages 6781-6795: The Stimulation of IGF-1R Expression by Lewis(y) Antigen Provides a Powerful Development Mechanism of Epithelial Ovarian Carcinoma</title>
	<link>http://www.mdpi.com/1422-0067/12/10/6781/</link>
	<description>Objective: This study aimed to measure and correlate the expression of insulin-like growth factor receptor-1 (IGF-1R) and the Lewis(y) antigen in ovarian cancer cell lines and tissue samples. Methods: Reverse transcriptase PCR (RT-PCR), Western blotting, immunoprecipitation, immunohistochemistry, and immunofluorescence double-labeling techniques were applied to detect and measure the expression of Lewis(y) and IGF-1R. Results: In α1,2-fucosyltransferase (α1,2-FT)-transfected cells, IGF-1R expression was significantly upregulated compared with cells that do not overexpress α1,2-FT (P &lt; 0.05). The amount of Lewis(y) expressed on IGF-1R increased 1.81-fold in α1,2-FT-overexpressing cells (P &lt; 0.05), but the ratio of Lewis(y) expressed on IGF-1R to total IGF-1R was unaltered between two cells (P &gt; 0.05). In malignant epithelial ovarian tumors, the positivity rates of Lewis(y) and IGF-1R detection were 88.3% and 93.33%, respectively, which is higher than the positivity rates in marginal (60.00% and 63.33%, all P &lt; 0.05), benign (33.00% and 53.33%, all P &lt; 0.01), and normal (0% and 40%, all P  0.05). Both IGF-1R and Lewis(y) were highly expressed in ovarian cancer tissues, and their expression levels were positively correlated (P &lt; 0.05). Conclusion: Overexpression of Lewis(y) results in overexpression of IGF-1R. Both IGF-1R and Lewis(y) are associated with the occurrence and development of ovarian cancers.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/10/6781/</guid>
	<pubDate>Fri, 14 Oct 2011 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-10-14</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>6781</prism:startingPage>
		<prism:endingPage>6795</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>The Stimulation of IGF-1R Expression by Lewis(y) Antigen Provides a Powerful Development Mechanism of Epithelial Ovarian Carcinoma</dc:title>
	<dc:date>2011-10-14</dc:date>
	<dc:identifier>doi: 10.3390/ijms12106781</dc:identifier>
		<dc:creator>Dawo Liu</dc:creator>
		<dc:creator>Juanjuan Liu</dc:creator>
		<dc:creator>Changzhi Wang</dc:creator>
		<dc:creator>Bei Lin</dc:creator>
		<dc:creator>Qing Liu</dc:creator>
		<dc:creator>Yingying Hao</dc:creator>
		<dc:creator>Shulan Zhang</dc:creator>
		<dc:creator>Masao Iwamori</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/10/6645/">
	<title>IJMS, Vol. 12, Pages 6645-6655: Expression of Elongation Factor (EF)-Tu Is Correlated with Prognosis of Gastric Adenocarcinomas</title>
	<link>http://www.mdpi.com/1422-0067/12/10/6645/</link>
	<description>Altered expressions of mitochondria elongation factor Tu (EF-Tu) have been observed in certain types of cancers, including gastric cancer cell lines, but the impact of the alterations in gastric adenocarcinoma remains unclear. The purpose of this study was to investigate the expression of EF-Tu in gastric adenocarcinoma and to assess its clinical significance. A total of 104 paired resected gastric adenocarcinoma and corresponding normal specimens were collected in this study. EF-Tu expression was assessed by immunohistochemical staining. The correlation of EF-Tu expression and patients’ clinicopathological parameters was statically evaluated and the prognostic significance of EF-Tu expression was assessed by univariate and multivariate analyses. Forty-nine out of 104 (47.1%) gastric adenocarcinoma specimens showed high expression of EF-Tu, while the remaining 55 specimens showed weak or negative expression of EF-Tu. In contrast, EF-Tu high expression was detected in 62.5% (65 of 104) normal tissues. Down-regulation of EF-Tu was associated with serosal invasion (P = 0.042) and node involvement (P = 0.005), and down-regulation of EF-Tu was correlated with poor overall survival (P = 0.020). In curative resection (R0) patients, there were also significant differences (P = 0.043). In the multivariate analysis, the EF-Tu expression remained a significant independent prognostic factor (P = 0.038). Our results indicate that EF-Tu is expressed in both gastric adenocarcinoma and corresponding normal tissues. Down-regulation of EF-Tu expression is associated with advanced disease stage and EF-Tu expression maybe served as an independent prognostic factor.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/10/6645/</guid>
	<pubDate>Mon, 10 Oct 2011 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-10-10</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>6645</prism:startingPage>
		<prism:endingPage>6655</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Expression of Elongation Factor (EF)-Tu Is Correlated with Prognosis of Gastric Adenocarcinomas</dc:title>
	<dc:date>2011-10-10</dc:date>
	<dc:identifier>doi: 10.3390/ijms12106645</dc:identifier>
		<dc:creator>Chaoyang Xu</dc:creator>
		<dc:creator>Jianjun Wang</dc:creator>
		<dc:creator>Jiajia Li</dc:creator>
		<dc:creator>Rengui Fang</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/9/5844/">
	<title>IJMS, Vol. 12, Pages 5844-5852: Nucleated Polymerisation in the Presence of Pre-Formed Seed Filaments</title>
	<link>http://www.mdpi.com/1422-0067/12/9/5844/</link>
	<description>We revisit the classical problem of nucleated polymerisation and derive a range of exact results describing polymerisation in systems intermediate between the well-known limiting cases of a reaction starting from purely soluble material and for a reaction where no new growth nuclei are formed.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/9/5844/</guid>
	<pubDate>Fri, 09 Sep 2011 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-09-09</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>5844</prism:startingPage>
		<prism:endingPage>5852</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Nucleated Polymerisation in the Presence of Pre-Formed Seed Filaments</dc:title>
	<dc:date>2011-09-09</dc:date>
	<dc:identifier>doi: 10.3390/ijms12095844</dc:identifier>
		<dc:creator>Samuel I. A. Cohen</dc:creator>
		<dc:creator>Michele Vendruscolo</dc:creator>
		<dc:creator>Christopher M. Dobson</dc:creator>
		<dc:creator>Tuomas P. J. Knowles</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/9/5461/">
	<title>IJMS, Vol. 12, Pages 5461-5470: Selection of Candidate Housekeeping Genes for Normalization in Human Postmortem Brain Samples</title>
	<link>http://www.mdpi.com/1422-0067/12/9/5461/</link>
	<description>The most frequently used technique to study the expression profile of genes involved in common neurological disorders is quantitative real-time RT-PCR, which allows the indirect detection of very low amounts of selected mRNAs in tissue samples. Expression analysis by RT-qPCR requires an appropriate normalization to the expression level of genes characterized by a stable, constitutive transcription. However, the identification of a gene transcribed at a very stable level is difficult if not impossible, since significant fluctuations of the level of mRNA synthesis often accompanies changes of cell behavior. The aim of this study is to identify the most stable genes in postmortem human brain samples of patients affected by Alzheimer’s disease (AD) suitable as reference genes. The experiments analyzed 12 commonly used reference genes in brain samples from eight individuals with AD and seven controls. After a careful analysis of the results calculated by geNorm and NormFinder algorithms, we found that CYC1 and EIF4A2 are the best reference genes. We remark on the importance of the determination of the best reference genes for each sample to be analyzed and suggest a practical combination of reference genes to be used in the analysis of human postmortem samples.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/9/5461/</guid>
	<pubDate>Fri, 26 Aug 2011 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-08-26</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Communication</prism:section>
	<prism:startingPage>5461</prism:startingPage>
		<prism:endingPage>5470</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Selection of Candidate Housekeeping Genes for Normalization in Human Postmortem Brain Samples</dc:title>
	<dc:date>2011-08-26</dc:date>
	<dc:identifier>doi: 10.3390/ijms12095461</dc:identifier>
		<dc:creator>Ilaria Penna</dc:creator>
		<dc:creator>Serena Vella</dc:creator>
		<dc:creator>Arianna Gigoni</dc:creator>
		<dc:creator>Claudio Russo</dc:creator>
		<dc:creator>Ranieri Cancedda</dc:creator>
		<dc:creator>Aldo Pagano</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/8/5052/">
	<title>IJMS, Vol. 12, Pages 5052-5059: A Pilot Study of the Association of Tumor Necrosis Factor Alpha Polymorphisms with Psoriatic Arthritis in the Romanian Population</title>
	<link>http://www.mdpi.com/1422-0067/12/8/5052/</link>
	<description>Tumor necrosis factor alpha (TNF-alpha) is an important pro-inflammatory cytokine implicated in the pathogenesis of psoriatic arthritis. We have performed a case-control association study of three TNF-alpha gene polymorphisms in a group of Romanian psoriatic arthritis patients versus ethnically matched controls. A second group of patients with undifferentiated spondyloarthritis was used in order to look for similarities in the genetic background of the two rheumatic disorders. The −857C/T polymorphism was associated with susceptibility to psoriatic arthritis in our population at the individual level (p = 0.03, OR 1.65, 95% CI 1.05–2.57) and in combined haplotypes with the −238G/A and −308G/A SNPs. Regarding the investigated polymorphisms and derived haplotypes, no potential association was found with the susceptibility to undifferentiated spondyloarthritis in Romanian patients.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/8/5052/</guid>
	<pubDate>Mon, 08 Aug 2011 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-08-08</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>5052</prism:startingPage>
		<prism:endingPage>5059</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>A Pilot Study of the Association of Tumor Necrosis Factor Alpha Polymorphisms with Psoriatic Arthritis in the Romanian Population</dc:title>
	<dc:date>2011-08-08</dc:date>
	<dc:identifier>doi: 10.3390/ijms12085052</dc:identifier>
		<dc:creator>Olivia M. Popa</dc:creator>
		<dc:creator>Mihai Bojinca</dc:creator>
		<dc:creator>Violeta Bojinca</dc:creator>
		<dc:creator>Monica I. Dutescu</dc:creator>
		<dc:creator>Mihaela Meirosu</dc:creator>
		<dc:creator>Ruxandra E. Caisan</dc:creator>
		<dc:creator>Claudia Ciofu</dc:creator>
		<dc:creator>Constantin Bara</dc:creator>
		<dc:creator>Luis O. Popa</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/5/3055/">
	<title>IJMS, Vol. 12, Pages 3055-3071: Genetic Diversity and Phylogeny of Antagonistic Bacteria against Phytophthora nicotianae Isolated from Tobacco Rhizosphere</title>
	<link>http://www.mdpi.com/1422-0067/12/5/3055/</link>
	<description>The genetic diversity of antagonistic bacteria from the tobacco rhizosphere was examined by BOXAIR-PCR, 16S-RFLP, 16S rRNA sequence homology and phylogenetic analysis methods. These studies revealed that 4.01% of the 6652 tested had some inhibitory activity against Phytophthora nicotianae. BOXAIR-PCR analysis revealed 35 distinct amplimers aligning at a 91% similarity level, reflecting a high degree of genotypic diversity among the antagonistic bacteria. A total of 25 16S-RFLP patterns were identified representing over 33 species from 17 different genera. Our results also found a significant amount of bacterial diversity among the antagonistic bacteria compared to other published reports. For the first time; Delftia tsuruhatensis, Stenotrophomonas maltophilia, Advenella incenata, Bacillus altitudinis, Kocuria palustris, Bacillus licheniformis, Agrobacterium tumefaciens and Myroides odoratimimus are reported to display antagonistic activity towards Phytophthora nicotianae. Furthermore, the majority (75%) of the isolates assayed for antagonistic activity were Gram-positives compared to only 25% that were Gram-negative bacteria.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/5/3055/</guid>
	<pubDate>Thu, 12 May 2011 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-05-12</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>3055</prism:startingPage>
		<prism:endingPage>3071</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Genetic Diversity and Phylogeny of Antagonistic Bacteria against Phytophthora nicotianae Isolated from Tobacco Rhizosphere</dc:title>
	<dc:date>2011-05-12</dc:date>
	<dc:identifier>doi: 10.3390/ijms12053055</dc:identifier>
		<dc:creator>Fengli Jin</dc:creator>
		<dc:creator>Yanqin Ding</dc:creator>
		<dc:creator>Wei Ding</dc:creator>
		<dc:creator>M.S. Reddy</dc:creator>
		<dc:creator>W.G. Dilantha Fernando</dc:creator>
		<dc:creator>Binghai Du</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/4/2477/">
	<title>IJMS, Vol. 12, Pages 2477-2487: YueF Overexpression Inhibits Cell Proliferation Partly through p21WAF1/Cip1 Upregulation in Renal Cell Carcinoma</title>
	<link>http://www.mdpi.com/1422-0067/12/4/2477/</link>
	<description>YueF is a novel putative tumor suppressor gene that can inhibit proliferation and induce apoptosis in hepatoma cells, but its role in renal cell carcinoma (RCC) remains unclear. Here, we examined the expression of the YueF gene in RCC tissues and the effect of YueF on cell proliferation in RCC 786-0 cells. The results showed that YueF was expressed at high levels in normal kidney tissues and cell lines but was reduced or absent in RCC tissues and 786-0 cells. Lentivirus-mediated YueF overexpression in RCC 786-0 cells caused cell-cycle arrest in the G1 phase and dramatically reduced proliferation in culture. YueF overexpression resulted in increased protein levels of p53 and p21WAF1/Cip1, whereas the protein levels of cyclin D1 and pRb were decreased. The proliferation defects caused by YueF overexpression could be partially rescued by the expression of p21 siRNA. These findings suggest a critical role for p21 in the YueF-induced growth inhibition of 786-0 cells and provide novel insights into the mechanism underlying the tumor-suppressive action of YueF.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/4/2477/</guid>
	<pubDate>Mon, 11 Apr 2011 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-04-11</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>2477</prism:startingPage>
		<prism:endingPage>2487</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>YueF Overexpression Inhibits Cell Proliferation Partly through p21WAF1/Cip1 Upregulation in Renal Cell Carcinoma</dc:title>
	<dc:date>2011-04-11</dc:date>
	<dc:identifier>doi: 10.3390/ijms12042477</dc:identifier>
		<dc:creator>Hsuan-Wei Huang</dc:creator>
		<dc:creator>Jian-Ping Peng</dc:creator>
		<dc:creator>Jie Zhang</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/3/1595/">
	<title>IJMS, Vol. 12, Pages 1595-1604: Cancer Stem-Like Cells Enriched in Panc-1 Spheres Possess Increased Migration Ability and Resistance to Gemcitabine</title>
	<link>http://www.mdpi.com/1422-0067/12/3/1595/</link>
	<description>Pancreatic cancer is one of the most lethal malignancies with poor prognosis. Previously, we found that a subpopulation of cancer stem cells (CSCs) in the Panc-1 pancreatic cancer cell line could propagate to form spheres. Here we characterized the malignant phenotypes of the pancreatic cancer stem CD44+/CD24+ cells, which were enriched under sphere forming conditions as analyzed by flow cytometry. These cells demonstrated increased resistance to gemcitabine and increased migration ability. Moreover, these cells exhibited epithelial to mesenchymal transition characterized by a decreased level of the epithelial marker E-cadherin and an increased level of the mesenchymal marker vimentin. Notably, abnormal expression of Bmi-1, ABCG2, Cyclin D1 and p16 were found in Panc-1 CSCs. Our results suggest that targeted inhibition of CSCs represents a novel therapeutic approach to overcome chemoresistance and metastasis of pancreatic cancer.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/3/1595/</guid>
	<pubDate>Tue, 01 Mar 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-03-01</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1595</prism:startingPage>
		<prism:endingPage>1604</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Cancer Stem-Like Cells Enriched in Panc-1 Spheres Possess Increased Migration Ability and Resistance to Gemcitabine</dc:title>
	<dc:date>2011-03-01</dc:date>
	<dc:identifier>doi: 10.3390/ijms12031595</dc:identifier>
		<dc:creator>Tao Yin</dc:creator>
		<dc:creator>Hongji Wei</dc:creator>
		<dc:creator>Shanmiao Gou</dc:creator>
		<dc:creator>Pengfei Shi</dc:creator>
		<dc:creator>Zhiyong Yang</dc:creator>
		<dc:creator>Gang Zhao</dc:creator>
		<dc:creator>Chunyou Wang</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/3/1533/">
	<title>IJMS, Vol. 12, Pages 1533-1562: Mechanisms of Estrogens’ Dose-Dependent Neuroprotective and Neurodamaging Effects in Experimental Models of Cerebral Ischemia</title>
	<link>http://www.mdpi.com/1422-0067/12/3/1533/</link>
	<description>Ever since the hypothesis was put forward that estrogens could protect against cerebral ischemia, numerous studies have investigated the mechanisms of their effects. Despite initial studies showing ameliorating effects, later trials in both humans and animals have yielded contrasting results regarding the fundamental issue of whether estrogens are neuroprotective or neurodamaging. Therefore, investigations of the possible mechanisms of estrogen actions in brain ischemia have been difficult to assess. A recently published systematic review from our laboratory indicates that the dichotomy in experimental rat studies may be caused by the use of insufficiently validated estrogen administration methods resulting in serum hormone concentrations far from those intended, and that physiological estrogen concentrations are neuroprotective while supraphysiological concentrations augment the damage from cerebral ischemia. This evidence offers a new perspective on the mechanisms of estrogens’ actions in cerebral ischemia, and also has a direct bearing on the hormone replacement therapy debate. Estrogens affect their target organs by several different pathways and receptors, and the mechanisms proposed for their effects on stroke probably prevail in different concentration ranges. In the current article, previously suggested neuroprotective and neurodamaging mechanisms are reviewed in a hormone concentration perspective in an effort to provide a mechanistic framework for the dose-dependent paradoxical effects of estrogens in stroke. It is concluded that five protective mechanisms, namely decreased apoptosis, growth factor regulation, vascular modulation, indirect antioxidant properties and decreased inflammation, and the proposed damaging mechanism of increased inflammation, are currently supported by experiments performed in optimal biological settings.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/3/1533/</guid>
	<pubDate>Fri, 25 Feb 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-02-25</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>3</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>1533</prism:startingPage>
		<prism:endingPage>1562</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Mechanisms of Estrogens’ Dose-Dependent Neuroprotective and Neurodamaging Effects in Experimental Models of Cerebral Ischemia</dc:title>
	<dc:date>2011-02-25</dc:date>
	<dc:identifier>doi: 10.3390/ijms12031533</dc:identifier>
		<dc:creator>Jakob O. Strom</dc:creator>
		<dc:creator>Annette Theodorsson</dc:creator>
		<dc:creator>Elvar Theodorsson</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/2/1334/">
	<title>IJMS, Vol. 12, Pages 1334-1358: Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation</title>
	<link>http://www.mdpi.com/1422-0067/12/2/1334/</link>
	<description>Claudin 4 is a cellular adhesion molecule that is frequently overexpressed in ovarian cancer and other epithelial cancers. In this study, we sought to determine whether the expression of claudin 4 is associated with outcome in ovarian cancer patients and may be involved in tumor progression. We examined claudin 4 expression in ovarian cancer tissues and cell lines, as well as by immunohistochemical staining of tissue microarrays (TMAs; n = 500), spheroids present in patients’ ascites, and spheroids formed in vitro. Claudin 4 was expressed in nearly 70% of the ovarian cancer tissues examined and was differentially expressed across ovarian cancer subtypes, with the lowest expression in clear cell subtype. No association was found between claudin 4 expression and disease-specific survival in any subtype. Claudin 4 expression was also observed in multicellular spheroids obtained from patients’ ascites. Using an in vitro spheroid formation assay, we found that NIH:OVCAR5 cells treated with shRNA against claudin 4 required a longer time to form compact spheroids compared to control NIH:OVCAR5 cells that expressed high levels of claudin 4. The inability of the NIH:OVCAR5 cells treated with claudin 4 shRNA to form compact spheroids was verified by FITC-dextran exclusion. These results demonstrate a role for claudin 4 and tight junctions in spheroid formation and integrity.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/2/1334/</guid>
	<pubDate>Tue, 22 Feb 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-02-22</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1334</prism:startingPage>
		<prism:endingPage>1358</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation</dc:title>
	<dc:date>2011-02-22</dc:date>
	<dc:identifier>doi: 10.3390/ijms12021334</dc:identifier>
		<dc:creator>Kristin L. M. Boylan</dc:creator>
		<dc:creator>Benjamin Misemer</dc:creator>
		<dc:creator>Melissa  S. DeRycke</dc:creator>
		<dc:creator>John  D. Andersen</dc:creator>
		<dc:creator>Katherine  M. Harrington</dc:creator>
		<dc:creator>Steve  E. Kalloger</dc:creator>
		<dc:creator>C. Blake Gilks</dc:creator>
		<dc:creator>Stefan  E. Pambuccian</dc:creator>
		<dc:creator>Amy  P. N. Skubitz</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/2/1306/">
	<title>IJMS, Vol. 12, Pages 1306-1315: The Effects of G-CSF on Proliferation of Mouse Myocardial Microvascular Endothelial Cells</title>
	<link>http://www.mdpi.com/1422-0067/12/2/1306/</link>
	<description>This paper explores the effect of granulocyte colony-stimulating factor (G-CSF) on mouse myocardial microvascular endothelial cell (CMECs) proliferation. CMECs were harvested from C57/BL6 mice. CMECs were cultured in medium containing G-CSF (0 ng/mL, 20 ng/mL, 40 ng/mL, 60 ng/mL) for five days. Proliferative activity of CMECs was examined by CCK-8 method. Hypoxia inducible factor-1 (HIF-1) and p53 expression levels was determined from the mRNA obtained by reverse transcription polymerase chain reaction (RT-PCR). Results showed that the purity quotient of the CMECs, which were cultured by the method of modified myocardial tissue explant culture, was higher than 95%. Compared with control untreated cells, the proliferative activity of CMECs and the expression level of HIF-1 mRNA in these cells were enhanced by G-CSF treatment, whereas the expression level of p53 mRNA was markedly reduced. It may be concluded that G-CSF could promote the proliferative activity of CMECs, which might be mediated by upregulation of HIF-1 and downregulation of p53.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/2/1306/</guid>
	<pubDate>Tue, 22 Feb 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-02-22</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1306</prism:startingPage>
		<prism:endingPage>1315</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>The Effects of G-CSF on Proliferation of Mouse Myocardial Microvascular Endothelial Cells</dc:title>
	<dc:date>2011-02-22</dc:date>
	<dc:identifier>doi: 10.3390/ijms12021306</dc:identifier>
		<dc:creator>Jiming Li</dc:creator>
		<dc:creator>Yunzeng Zou</dc:creator>
		<dc:creator>Junbo Ge</dc:creator>
		<dc:creator>Daifu Zhang</dc:creator>
		<dc:creator>Aili Guan</dc:creator>
		<dc:creator>Jian Wu</dc:creator>
		<dc:creator>Lei Li</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/2/1222/">
	<title>IJMS, Vol. 12, Pages 1222-1231: Role of Rho Kinase in Microvascular Damage Following Cerebral Ischemia Reperfusion in Rats</title>
	<link>http://www.mdpi.com/1422-0067/12/2/1222/</link>
	<description>Rho kinase (ROCK) is a well-known downstream effector of Rho and plays an important role in various physiopathological processes. In this study, we aim to investigate the correlation between ROCK and microvascular damage in rat brain subjected to middle cerebral artery occlusion (MCAO) and reperfusion, and to elucidate the mechanisms underlying the microvascular damage. ROCK and matrix metalloproteinase 9 (MMP9) mRNA levels were determined by real time quantitative PCR, Laminin was detected by immunofluorescence and Blood Brain Barrier (BBB) permeability was examined by Evans Blue (EB) in rat MCAO models. We observed similar patterns of changes in ROCK expression, brain EB content, and Laminin expression at different time points after brain ischemia. Statistical analysis further confirmed a significant linear correlation of ROCK expression with the onset of microvascular damage in brain. Furthermore, the ROCK inhibitor fasudil decreased brain EB content but increased Laminin expression. These results provide strong evidence that ROCK mediates microvascular damage. In addition, we found that fasudil could significantly inhibit MMP9 expression induced by ischemia. Thus, our findings suggest that ROCK promotes microvascular damage by upregulating MMP9 and reveal ROCK as a promising therapeutic target for stroke.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/2/1222/</guid>
	<pubDate>Fri, 18 Feb 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-02-18</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1222</prism:startingPage>
		<prism:endingPage>1231</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Role of Rho Kinase in Microvascular Damage Following Cerebral Ischemia Reperfusion in Rats</dc:title>
	<dc:date>2011-02-18</dc:date>
	<dc:identifier>doi: 10.3390/ijms12021222</dc:identifier>
		<dc:creator>Kang Liu</dc:creator>
		<dc:creator>Zhen Li</dc:creator>
		<dc:creator>Tao Wu</dc:creator>
		<dc:creator>Suju Ding</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/2/1133/">
	<title>IJMS, Vol. 12, Pages 1133-1145: Expression and Clinical Role of Protein of Regenerating Liver (PRL) Phosphatases in Ovarian Carcinoma</title>
	<link>http://www.mdpi.com/1422-0067/12/2/1133/</link>
	<description>The present study analyzed the expression and clinical role of the protein of regenerating liver (PRL) phosphatase family in ovarian carcinoma. PRL1-3 mRNA expression was studied in 184 tumors (100 effusions, 57 primary carcinomas, 27 solid metastases) using RT-PCR. PRL-3 protein expression was analyzed in 157 tumors by Western blotting. PRL-1 mRNA levels were significantly higher in effusions compared to solid tumors (p</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/2/1133/</guid>
	<pubDate>Fri, 11 Feb 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-02-11</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1133</prism:startingPage>
		<prism:endingPage>1145</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Expression and Clinical Role of Protein of Regenerating Liver (PRL) Phosphatases in Ovarian Carcinoma</dc:title>
	<dc:date>2011-02-11</dc:date>
	<dc:identifier>doi: 10.3390/ijms12021133</dc:identifier>
		<dc:creator>Reuven Reich</dc:creator>
		<dc:creator>Shany Hadar</dc:creator>
		<dc:creator>Ben Davidson</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/2/1009/">
	<title>IJMS, Vol. 12, Pages 1009-1029: Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis</title>
	<link>http://www.mdpi.com/1422-0067/12/2/1009/</link>
	<description>There is increasing evidence to suggest that extracellular matrix (ECM) components play an active role in tumor progression and are an important determinant for the growth and progression of solid tumors. Tumor cells interfere with the normal programming of ECM biosynthesis and can extensively modify the structure and composition of the matrix. In ovarian cancer alterations in the extracellular environment are critical for tumor initiation and progression and intra-peritoneal dissemination. ECM molecules including versican and hyaluronan (HA) which interacts with the HA receptor, CD44, have been shown to play critical roles in ovarian cancer metastasis. This review focuses on versican, HA, and CD44 and their potential as therapeutic targets for ovarian cancer.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/2/1009/</guid>
	<pubDate>Mon, 31 Jan 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-01-31</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>1009</prism:startingPage>
		<prism:endingPage>1029</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis</dc:title>
	<dc:date>2011-01-31</dc:date>
	<dc:identifier>doi: 10.3390/ijms12021009</dc:identifier>
		<dc:creator>Miranda  P. Ween</dc:creator>
		<dc:creator>Martin  K. Oehler</dc:creator>
		<dc:creator>Carmela Ricciardelli</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/2/983/">
	<title>IJMS, Vol. 12, Pages 983-1008: Epigenetic Regulation of Cancer-Associated Genes in Ovarian Cancer</title>
	<link>http://www.mdpi.com/1422-0067/12/2/983/</link>
	<description>The involvement of epigenetic aberrations in the development and progression of tumors is now well established. However, most studies have focused on the epigenetic inactivation of tumor suppressor genes during tumorigenesis and little is known about the epigenetic activation of cancer-associated genes, except for the DNA hypomethylation of some genes. Recently, we reported that the overexpression of cancer-promoting genes in ovarian cancer is associated with the loss of repressive histone modifications. This discovery suggested that epigenetic derepression may contribute to ovarian tumorigenesis by constituting a possible mechanism for the overexpression of oncogenes or cancer-promoting genes in tumors. The emerging importance of epigenetic aberrations in tumor initiation and in the regulation of cancer-initiating cells, suggests that epigenetically regulated genes may be promising therapeutic targets and biomarkers. Given that the current challenges in ovarian cancer include the identification of biomarkers for early cancer detection and the discovery of novel therapeutic targets for patients with recurrent malignancies undergoing chemotherapy, understanding the epigenetic changes that occur in ovarian cancer is crucial. This review looks at epigenetic mechanisms involved in the regulation of cancer-associated genes, including the contribution of epigenetic derepression to the activation of cancer-associated genes in ovarian cancer. In addition, possible epigenetic therapies targeting epigenetically dysregulated genes are discussed. A better understanding of the epigenetic changes in ovarian cancer will contribute to the improvement of patient outcomes.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/2/983/</guid>
	<pubDate>Mon, 31 Jan 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-01-31</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>983</prism:startingPage>
		<prism:endingPage>1008</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Epigenetic Regulation of Cancer-Associated Genes in Ovarian Cancer</dc:title>
	<dc:date>2011-01-31</dc:date>
	<dc:identifier>doi: 10.3390/ijms12020983</dc:identifier>
		<dc:creator>Mi Jeong Kwon</dc:creator>
		<dc:creator>Young Kee Shin</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/2/971/">
	<title>IJMS, Vol. 12, Pages 971-982: Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer</title>
	<link>http://www.mdpi.com/1422-0067/12/2/971/</link>
	<description>Ovarian cancer, one of the most common gynecological malignancies, has an aggressive phenotype. It is necessary to develop novel and more effective treatment strategies against advanced disease. Protein tyrosine kinases (PTKs) play an important role in the signal transduction pathways involved in tumorigenesis, and represent potential targets for anticancer therapies. In this study, we performed cDNA subtraction following polymerase chain reaction (PCR) using degenerate oligonucleotide primers to identify specifically overexpressed PTKs in ovarian cancer. Three PTKs, janus kinase 1, insulin-like growth factor 1 receptor, and discoidin domain receptor 1 (DDR1), were identified and only DDR1 was overexpressed in all ovarian cancer tissues examined for the validation by quantitative real-time PCR. The DDR1 protein was expressed in 63% (42/67) of serous ovarian cancer tissue, whereas it was undetectable in normal ovarian surface epithelium. DDR1 was expressed significantly more frequently in high-grade (79%) and advanced stage (77%) tumors compared to low-grade (50%) and early stage (43%) tumors. The expression of the DDR1 protein significantly correlated with poor disease-free survival. Although its functional role and clinical utility remain to be examined in future studies, our results suggest that the expression of DDR1 may serve as both a potential biomarker and a molecular target for advanced ovarian cancer.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/2/971/</guid>
	<pubDate>Mon, 31 Jan 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-01-31</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>971</prism:startingPage>
		<prism:endingPage>982</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer</dc:title>
	<dc:date>2011-01-31</dc:date>
	<dc:identifier>doi: 10.3390/ijms12020971</dc:identifier>
		<dc:creator>Jinhua Quan</dc:creator>
		<dc:creator>Tetsuro Yahata</dc:creator>
		<dc:creator>Sosuke Adachi</dc:creator>
		<dc:creator>Kosuke Yoshihara</dc:creator>
		<dc:creator>Kenichi Tanaka</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/1/773/">
	<title>IJMS, Vol. 12, Pages 773-794: MALDI Imaging Mass Spectrometry (MALDI-IMS)―Application of Spatial Proteomics for Ovarian Cancer Classification and Diagnosis</title>
	<link>http://www.mdpi.com/1422-0067/12/1/773/</link>
	<description>MALDI imaging mass spectrometry (MALDI-IMS) allows acquisition of mass data for metabolites, lipids, peptides and proteins directly from tissue sections. IMS is typically performed either as a multiple spot profiling experiment to generate tissue specific mass profiles, or a high resolution imaging experiment where relative spatial abundance for potentially hundreds of analytes across virtually any tissue section can be measured. Crucially, imaging can be achieved without prior knowledge of tissue composition and without the use of antibodies. In effect MALDI-IMS allows generation of molecular data which complement and expand upon the information provided by histology including immuno-histochemistry, making its application valuable to both cancer biomarker research and diagnostics. The current state of MALDI-IMS, key biological applications to ovarian cancer research and practical considerations for analysis of peptides and proteins on ovarian tissue are presented in this review.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/1/773/</guid>
	<pubDate>Fri, 21 Jan 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-01-21</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>773</prism:startingPage>
		<prism:endingPage>794</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>MALDI Imaging Mass Spectrometry (MALDI-IMS)―Application of Spatial Proteomics for Ovarian Cancer Classification and Diagnosis</dc:title>
	<dc:date>2011-01-21</dc:date>
	<dc:identifier>doi: 10.3390/ijms12010773</dc:identifier>
		<dc:creator>Johan O. R. Gustafsson</dc:creator>
		<dc:creator>Martin K. Oehler</dc:creator>
		<dc:creator>Andrew Ruszkiewicz</dc:creator>
		<dc:creator>Shaun R. McColl</dc:creator>
		<dc:creator>Peter Hoffmann</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/1/694/">
	<title>IJMS, Vol. 12, Pages 694-724: In Silico Theoretical Molecular Modeling for Alzheimer’s Disease: The Nicotine-Curcumin Paradigm in Neuroprotection and Neurotherapy</title>
	<link>http://www.mdpi.com/1422-0067/12/1/694/</link>
	<description>The aggregation of the amyloid-β-peptide (AβP) into well-ordered fibrils has been considered as the key pathological marker of Alzheimer’s disease. Molecular attributes related to the specific binding interactions, covalently and non-covalently, of a library of compounds targeting of conformational scaffolds were computed employing static lattice atomistic simulations and array constructions. A combinatorial approach using isobolographic analysis was stochastically modeled employing Artificial Neural Networks and a Design of Experiments approach, namely an orthogonal Face-Centered Central Composite Design for small molecules, such as curcumin and glycosylated nornicotine exhibiting concentration-dependent behavior on modulating AβP aggregation and oligomerization. This work provides a mathematical and in silico approach that constitutes a new frontier in providing neuroscientists with a template for in vitro and in vivo experimentation. In future this could potentially allow neuroscientists to adopt this in silico approach for the development of novel therapeutic interventions in the neuroprotection and neurotherapy of Alzheimer’s disease. In addition, the neuroprotective entities identified in this study may also be valuable in this regard.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/1/694/</guid>
	<pubDate>Wed, 19 Jan 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-01-19</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>694</prism:startingPage>
		<prism:endingPage>724</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>In Silico Theoretical Molecular Modeling for Alzheimer’s Disease: The Nicotine-Curcumin Paradigm in Neuroprotection and Neurotherapy</dc:title>
	<dc:date>2011-01-19</dc:date>
	<dc:identifier>doi: 10.3390/ijms12010694</dc:identifier>
		<dc:creator>Pradeep Kumar</dc:creator>
		<dc:creator>Viness Pillay</dc:creator>
		<dc:creator>Yahya E. Choonara</dc:creator>
		<dc:creator>Girish Modi</dc:creator>
		<dc:creator>Dinesh Naidoo</dc:creator>
		<dc:creator>Lisa C. Du Toit</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/1/668/">
	<title>IJMS, Vol. 12, Pages 668-681: Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo</title>
	<link>http://www.mdpi.com/1422-0067/12/1/668/</link>
	<description>The present study was designed to investigate the combined effects of cyclooxygenase (COX)-1 and COX-2 selective inhibitors on human ovarian SKOV-3 carcinoma cells xenograft-bearing mice. The animals were treated with 3 mg/kg SC-560 (a COX-1 selective inhibitor) alone, 25 mg/kg celecoxib (a COX-2 selective inhibitor) alone, or SC-560/celecoxib by gavage, twice a day for three weeks. To test the mechanism of inhibition of tumor growth by COX selective inhibitors, the index of proliferating cells in tumor tissues was determined by immunostaining and the index of apoptotic cells by the terminal-deoxynucleotidyl-transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) method. The inhibitory rate on tumor growth in the combination group was 35.54% which is significant statistically compared with that of the control group (P &lt; 0.05). In the combination group, the index of cell proliferation and apoptosis were 12.40% and 51.03% respectively, which are significant statistically compared with those of the control group (22.56%, 19.07%, all P &lt; 0.05). These studies indicate that synergism between two COX inhibitors and inhibitor combination treatment has particular potential for chemoprevention of ovarian cancer growth.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/1/668/</guid>
	<pubDate>Tue, 18 Jan 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-01-18</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>668</prism:startingPage>
		<prism:endingPage>681</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Combined Effects of Cyclooxygenase-1 and Cyclooxygenase-2 Selective Inhibitors on Ovarian Carcinoma in Vivo</dc:title>
	<dc:date>2011-01-18</dc:date>
	<dc:identifier>doi: 10.3390/ijms12010668</dc:identifier>
		<dc:creator>Wei Li</dc:creator>
		<dc:creator>Jie Wang</dc:creator>
		<dc:creator>Hong-Ru Jiang</dc:creator>
		<dc:creator>Xiao-Li Xu</dc:creator>
		<dc:creator>Jun Zhang</dc:creator>
		<dc:creator>Mei-Lin Liu</dc:creator>
		<dc:creator>Ling-Yun Zhai</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/1/613/">
	<title>IJMS, Vol. 12, Pages 613-626: Construction and Characterization of a cDNA Library from Wheat Infected with Fusarium graminearum Fg 2</title>
	<link>http://www.mdpi.com/1422-0067/12/1/613/</link>
	<description>Total RNA from wheat spikes infected with F. graminearum Fg2 was extracted and the mRNA was purified. Switching Mechanism at 5' end of the RNA Transcript (SMART) technique and CDS Ill/3' primer were used for first-strand cDNA synthesis using reverse transcriptase by RT-PCR. Primer extension polymerase chain reaction was used to construct the double-strand cDNA that was digested by proteinase K, then by Sfi I and fractionated. cDNAs longer than 0.5 kb were collected and ligated to λTriplEx2 vector followed λ phage packaging reaction and library amplification. The qualities of both unamplified and amplified cDNA libraries were strictly checked by conventional titer determination. One hundred and sixty five plaques were randomly picked and tested using PCR with universal primers derived from the sequence flanking the vector. A high quality cDNA library from wheat spikes that have been infected by F. graminearum was successfully constructed.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/1/613/</guid>
	<pubDate>Tue, 18 Jan 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-01-18</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>613</prism:startingPage>
		<prism:endingPage>626</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Construction and Characterization of a cDNA Library from Wheat Infected with Fusarium graminearum Fg 2</dc:title>
	<dc:date>2011-01-18</dc:date>
	<dc:identifier>doi: 10.3390/ijms12010613</dc:identifier>
		<dc:creator>Khaled Al-Taweel</dc:creator>
		<dc:creator>W. G. Dilantha Fernando</dc:creator>
		<dc:creator>Anita L. Brûlé-Babel</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/1/506/">
	<title>IJMS, Vol. 12, Pages 506-569: The Biochemical and Cellular Basis for Nutraceutical Strategies to Attenuate Neurodegeneration in Parkinson’s Disease</title>
	<link>http://www.mdpi.com/1422-0067/12/1/506/</link>
	<description>Future therapeutic intervention that could effectively decelerate the rate of degeneration within the substantia nigra pars compacta (SNc) could add years of mobility and reduce morbidity associated with Parkinson’s disease (PD). Neurodegenerative decline associated with PD is distinguished by extensive damage to SNc dopaminergic (DAergic) neurons and decay of the striatal tract. While genetic mutations or environmental toxins can precipitate pathology, progressive degenerative succession involves a gradual decline in DA neurotransmission/synaptic uptake, impaired oxidative glucose consumption, a rise in striatal lactate and chronic inflammation. Nutraceuticals play a fundamental role in energy metabolism and signaling transduction pathways that control neurotransmission and inflammation. However, the use of nutritional supplements to slow the progression of PD has met with considerable challenge and has thus far proven unsuccessful. This review re-examines precipitating factors and insults involved in PD and how nutraceuticals can affect each of these biological targets. Discussed are disease dynamics (Sections 1 and 2) and natural substances, vitamins and minerals that could impact disease processes (Section 3). Topics include nutritional influences on α-synuclein aggregation, ubiquitin proteasome function, mTOR signaling/lysosomal-autophagy, energy failure, faulty catecholamine trafficking, DA oxidation, synthesis of toxic DA-quinones, o-semiquinones, benzothiazolines, hyperhomocyseinemia, methylation, inflammation and irreversible oxidation of neuromelanin. In summary, it is clear that future research will be required to consider the multi-faceted nature of this disease and re-examine how and why the use of nutritional multi-vitamin-mineral and plant-based combinations could be used to slow the progression of PD, if possible.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/1/506/</guid>
	<pubDate>Mon, 17 Jan 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-01-17</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>506</prism:startingPage>
		<prism:endingPage>569</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>The Biochemical and Cellular Basis for Nutraceutical Strategies to Attenuate Neurodegeneration in Parkinson’s Disease</dc:title>
	<dc:date>2011-01-17</dc:date>
	<dc:identifier>doi: 10.3390/ijms12010506</dc:identifier>
		<dc:creator>Elizabeth A. Mazzio</dc:creator>
		<dc:creator>Fran Close</dc:creator>
		<dc:creator>Karam F.A. Soliman</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/12/1/410/">
	<title>IJMS, Vol. 12, Pages 410-428: Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery</title>
	<link>http://www.mdpi.com/1422-0067/12/1/410/</link>
	<description>Most scientific efforts towards early detection of ovarian cancer are commonly focused on the discovery of tumour-associated antigens (TAA). Autologous antibodies against TAA, however, may serve as more sensitive diagnostic markers. They circulate in the blood before TAA and are usually more abundant than the TAAs themselves as a result of amplification through the humoral immune response. Accumulating evidence also suggests that a humoral response already exists during malignant transformation when aberrant gene expression is translated into premalignant cellular changes. This article reviews the current knowledge about autoantibodies against TAA in ovarian cancer and presents current immunoproteomic approaches for their detection.</description>
	
	<guid>http://www.mdpi.com/1422-0067/12/1/410/</guid>
	<pubDate>Fri, 14 Jan 2011 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2011-01-14</prism:publicationDate>
	<prism:volume>12</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>410</prism:startingPage>
		<prism:endingPage>428</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery</dc:title>
	<dc:date>2011-01-14</dc:date>
	<dc:identifier>doi: 10.3390/ijms12010410</dc:identifier>
		<dc:creator>Karina Martin</dc:creator>
		<dc:creator>Carmela Ricciardelli</dc:creator>
		<dc:creator>Peter Hoffmann</dc:creator>
		<dc:creator>Martin K. Oehler</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/12/5120/">
	<title>IJMS, Vol. 11, Pages 5120-5128: Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma</title>
	<link>http://www.mdpi.com/1422-0067/11/12/5120/</link>
	<description>Recent genome-wide analysis has demonstrated that somatic mutations in ARID1A (BAF250) are the most common molecular genetic changes in ovarian clear cell carcinoma (OCCC). ARID1A mutations, which occur in approximately half of OCCC cases, lead to deletion of the encoded protein and inactivation of the putative tumor suppressor. In this study, we determined the significance of loss of ARID1A immunoreactivity with respect to several clinicopathological features in a total of 149 OCCCs. First, we demonstrated that ARID1A immunohistochemistry showed concordance with the mutational status in 91% of cases with 100% sensitivity and 66% specificity. Specifically, among 12 OCCC cases for which ARIDA mutational status was known, ARIDIA immunoreactivity was undetectable in all 9 cases harboring ARID1A mutations and was undetectable in one of 3 cases with wild-type ARID1A. With respect to the entire cohort, ARID1A immunoreactivity was undetectable in 88 (59%) of 149 OCCCs. There was no significant difference between ARID1A negative and positive cases in terms of histopathologic features, age, clinical stage, or overall survival. In conclusion, this study provides further evidence that mutations in ARID1A resulted in loss of ARID1A protein expression in OCCC, although no significant differences between ARID1A positive and negative cases were observed with respect to any clinicopathological features examined.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/12/5120/</guid>
	<pubDate>Mon, 13 Dec 2010 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-12-13</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>12</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>5120</prism:startingPage>
		<prism:endingPage>5128</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma</dc:title>
	<dc:date>2010-12-13</dc:date>
	<dc:identifier>doi: 10.3390/ijms11125120</dc:identifier>
		<dc:creator>Daichi Maeda</dc:creator>
		<dc:creator>Tsui-Lien Mao</dc:creator>
		<dc:creator>Masashi Fukayama</dc:creator>
		<dc:creator>Shunsuke Nakagawa</dc:creator>
		<dc:creator>Tetsu Yano</dc:creator>
		<dc:creator>Yuji Taketani</dc:creator>
		<dc:creator>Ie-Ming Shih</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/11/4580/">
	<title>IJMS, Vol. 11, Pages 4580-4590: Neuroprotective Properties of Picroside II in a Rat Model of Focal Cerebral Ischemia</title>
	<link>http://www.mdpi.com/1422-0067/11/11/4580/</link>
	<description>The aim of this study was to explore the effect of picroside II on neuronal apoptosis and the expression of caspase-3 and poly ADP-ribose polymerase (PARP) following middle cerebral artery occlusion/reperfusion in male Wistar rats. Picroside II (10 mg/kg) was administered intravenously into the tail vein of the animals. The neurological function deficits were evaluated with the Bederson’s test and the cerebral infarction volume was visualized with tetrazolium chloride (TTC) staining. The apoptotic cells were counted by in situ terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick end labeling (TUNEL) assay. The immunohistochemistry stain and enzyme linked immunosorbent assay (ELISA) was used to determine the expressions of caspase-3 and PARP in brain tissue. The results indicated that rats in the control group showed neurological function deficit and cerebral infarction in ischemic hemisphere after two hours ischemia followed by 22 hours reperfusion. Caspase-3 and PARP expressions were also profound in the cortex, the striatum and the hippocampus, along with increased apoptotic cells in this group. Bederson's score, infarction volume, and expressions of caspase-3 and PARP, as well as apoptosis in the treatment group were, however, significantly decreased compared to those in the control group indicating that intravenous treatment with picroside II might be beneficial to inhibit neuronal apoptosis and, thus, to improve the neurological function of rats upon cerebral ischemia reperfusion injury.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/11/4580/</guid>
	<pubDate>Tue, 16 Nov 2010 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-11-16</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>4580</prism:startingPage>
		<prism:endingPage>4590</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Neuroprotective Properties of Picroside II in a Rat Model of Focal Cerebral Ischemia</dc:title>
	<dc:date>2010-11-16</dc:date>
	<dc:identifier>doi: 10.3390/ijms11114580</dc:identifier>
		<dc:creator>Qin Li</dc:creator>
		<dc:creator>Zhen Li</dc:creator>
		<dc:creator>Xin-ying Xu</dc:creator>
		<dc:creator>Yun-liang Guo</dc:creator>
		<dc:creator>Fang Du</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/11/4465/">
	<title>IJMS, Vol. 11, Pages 4465-4487: Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease</title>
	<link>http://www.mdpi.com/1422-0067/11/11/4465/</link>
	<description>Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) that was generated via a unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6‑OHDA). We assessed the expression of cell biomarkers that are involved in signaling cascades and provide neural and glial integration: the neuronal marker TH (tyrosine hydroxylase); ubiquitin (a regulatory peptide involved in the ubiquitin-proteasome degradation system); Notch-3 (a marker of progenitor cells); IBA-1 (a marker of microglial cells); glial fibrillary acidic protein, GFAP (a marker of astrocytes); and inducible nitric oxide synthase, iNOS (a marker of inflammation). The data show that in the 6-OHDA-lesioned striatum, mildronate completely prevented the loss of TH, stimulated Notch-3 expression and decreased the expression of ubiquitin, GFAP and iNOS. These results provide evidence for the ability of mildronate to control the expression of an array of cellular proteins and, thus, impart multi-faceted homeostatic mechanisms in neurons and glial cells in a rat model of PD. We suggest that the use of mildronate provides a protective effect during the early stages of PD that can delay or halt the progression of this neurodegenerative disease.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/11/4465/</guid>
	<pubDate>Tue, 09 Nov 2010 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-11-09</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>4465</prism:startingPage>
		<prism:endingPage>4487</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease</dc:title>
	<dc:date>2010-11-09</dc:date>
	<dc:identifier>doi: 10.3390/ijms11114465</dc:identifier>
		<dc:creator>Vija Z. Klusa</dc:creator>
		<dc:creator>Sergejs Isajevs</dc:creator>
		<dc:creator>Darja Svirina</dc:creator>
		<dc:creator>Jolanta Pupure</dc:creator>
		<dc:creator>Ulrika Beitnere</dc:creator>
		<dc:creator>Juris Rumaks</dc:creator>
		<dc:creator>Simons Svirskis</dc:creator>
		<dc:creator>Baiba Jansone</dc:creator>
		<dc:creator>Zane Dzirkale</dc:creator>
		<dc:creator>Ruta Muceniece</dc:creator>
		<dc:creator>Ivars Kalvinsh</dc:creator>
		<dc:creator>Harry V. Vinters</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/11/4441/">
	<title>IJMS, Vol. 11, Pages 4441-4451: Lewis (y) Antigen Overexpression Increases the Expression of MMP-2 and MMP-9 and Invasion of Human Ovarian Cancer Cells</title>
	<link>http://www.mdpi.com/1422-0067/11/11/4441/</link>
	<description>Lewis (y) antigen is a difucosylated oligosaccharide present on the plasma membrane, and its overexpression is frequently found in human cancers and has been shown to be associated with poor prognosis. Our previous studies have shown that Lewis (y) antigen plays a positive role in the process of invasion and metastasis of ovarian cancer cells. However, the mechanisms by which Lewis (y) antigen enhances the invasion and tumor metastasis are still unknown. In this study, we established a stable cell line constitutively expressing Lewis (y) antigen (RMG-1-hFUT) by transfecting the cDNA encoding part of the human α1,2-fucosyltransferase (α1,2-FUT) gene into the ovarian cancer cell line RMG-1, and investigated whether Lewis (y) antigen regulates the expression of matrix metalloproteinase-2 (MMP-2) and MMP-9, and tissue inhibitors of metalloproteinases (TIMP-1) and TIMP-2. We found that RMG-1-hFUT cells exhibited higher invasive capacities than their control cells. In addition, expression of TIMP-1 and TIMP-2 was down-regulated and expression of MMP-2 and MMP-9 was up-regulated. Anti-Lewis (y) antigen antibody treatment significantly reversed the expression of TIMP-1, TIMP-2, MMP-2 and MMP-9. Taken together, we provide the first evidence that down-regulation of TIMP-1 and TIMP-2 and up-regulation of MMP-2 and MMP-9 represents one of the mechanisms by which Lewis (y) antigen promotes cell invasion.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/11/4441/</guid>
	<pubDate>Mon, 08 Nov 2010 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-11-08</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>11</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>4441</prism:startingPage>
		<prism:endingPage>4451</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Lewis (y) Antigen Overexpression Increases the Expression of MMP-2 and MMP-9 and Invasion of Human Ovarian Cancer Cells</dc:title>
	<dc:date>2010-11-08</dc:date>
	<dc:identifier>doi: 10.3390/ijms11114441</dc:identifier>
		<dc:creator>Limei Yan</dc:creator>
		<dc:creator>Bei Lin</dc:creator>
		<dc:creator>Lili Gao</dc:creator>
		<dc:creator>Song Gao</dc:creator>
		<dc:creator>Chuan Liu</dc:creator>
		<dc:creator>Changzhi Wang</dc:creator>
		<dc:creator>Yifei Wang</dc:creator>
		<dc:creator>Shulan Zhang</dc:creator>
		<dc:creator>Masao Iwamori</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/10/3999/">
	<title>IJMS, Vol. 11, Pages 3999-4013: Cyclin D1 Expression and the Inhibitory Effect of Celecoxib on Ovarian Tumor Growth in Vivo</title>
	<link>http://www.mdpi.com/1422-0067/11/10/3999/</link>
	<description>The report aims to investigate the relationship between the expression of cyclin D1 and Cyclooxgenase-2 (COX-2), thus to explore the molecular mechanisms of the antitumor efficacy of Celecoxib, a COX-2 inhibitor. Human ovarian SKOV-3 carcinoma cell xenograft-bearing mice were treated with Celecoxib by infusing gaster (i.g.) twice/day for 21 days. The mRNA levels of COX-2 and cyclin D1 were determined by RT-PCR. The expression of cyclin D1 at the protein level was detected by immunohistochemistry, while COX-2 protein expression was determined by Western blot. A high-dose of Celecoxib (100 mg/kg) significantly inhibited tumor growth (P &lt; 0.05), and the expression of cyclin D1 was reduced by 61%. Celecoxib decreased the proliferation cell index by 40% (P &lt; 0.001) and increased apoptotic index by 52% (P &lt; 0.05) in high-dose Celecoxib treated group. Our results suggest that the antitumor efficacy of Celecoxib against ovarian cancer in mice may in part be mediated through suppression of cyclin D1, which may contribute to its ability to suppress proliferation.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/10/3999/</guid>
	<pubDate>Tue, 19 Oct 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-10-19</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>3999</prism:startingPage>
		<prism:endingPage>4013</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Cyclin D1 Expression and the Inhibitory Effect of Celecoxib on Ovarian Tumor Growth in Vivo</dc:title>
	<dc:date>2010-10-19</dc:date>
	<dc:identifier>doi: 10.3390/ijms11103999</dc:identifier>
		<dc:creator>Wei Li</dc:creator>
		<dc:creator>Hong-Ru Jiang</dc:creator>
		<dc:creator>Xiao-Li Xu</dc:creator>
		<dc:creator>Jie Wang</dc:creator>
		<dc:creator>Jun Zhang</dc:creator>
		<dc:creator>Mei-Lin Liu</dc:creator>
		<dc:creator>Ling-Yun Zhai</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/10/3748/">
	<title>IJMS, Vol. 11, Pages 3748-3759: Lewis Y Promotes Growth and Adhesion of Ovarian Carcinoma-Derived RMG-I Cells by Upregulating Growth Factors</title>
	<link>http://www.mdpi.com/1422-0067/11/10/3748/</link>
	<description>Lewis y (LeY) antigen is a difucosylated oligosaccharide carried by glycoconjugates on the cell surface. Overexpression of LeY is frequently observed in epithelial-derived cancers and has been correlated to the pathological staging and prognosis. However, the effects of LeY on ovarian cancer are not yet clear. Previously, we transfected the ovarian cancer cell line RMG-I with the α1,2-fucosyltransferase gene to obtain stable transfectants, RMG-I-H, that highly express LeY. In the present study, we examined the proliferation, tumorigenesis, adhesion and invasion of the cell lines with treatment of LeY monoclonal antibody (mAb). Additionally, we examined the expression of TGF-β1, VEGF and b-FGF in xenograft tumors. The results showed that the proliferation and adhesion in vitro were significantly inhibited by treatment of RMG-I-H cells with LeY mAb. When subcutaneously inoculated in nude mice, RMG-I-H cells produced large tumors, while mock-transfected cells RMG-I-C and the parental cells RMG-I produced small tumors. Moreover, the tumor formation by RMG-I-H cells was inhibited by preincubating the cells with LeY mAb. Notably, the expression of TGF-β1, VEGF and b-FGF all increased in RMG-I-H cells. In conclusion, LeY plays an important role in promoting cell proliferation, tumorigenecity and adhesion, and these effects may be related to increased levels of growth factors. The LeY antibody shows potential application in the treatment of LeY-positive tumors.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/10/3748/</guid>
	<pubDate>Wed, 29 Sep 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-09-29</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>10</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>3748</prism:startingPage>
		<prism:endingPage>3759</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Lewis Y Promotes Growth and Adhesion of Ovarian Carcinoma-Derived RMG-I Cells by Upregulating Growth Factors</dc:title>
	<dc:date>2010-09-29</dc:date>
	<dc:identifier>doi: 10.3390/ijms11103748</dc:identifier>
		<dc:creator>Feifei Li</dc:creator>
		<dc:creator>Bei Lin</dc:creator>
		<dc:creator>Yingying Hao</dc:creator>
		<dc:creator>Yan Li</dc:creator>
		<dc:creator>Juanjuan Liu</dc:creator>
		<dc:creator>Jianping Cong</dc:creator>
		<dc:creator>Liancheng Zhu</dc:creator>
		<dc:creator>Qing Liu</dc:creator>
		<dc:creator>Shulan Zhang</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/9/3513/">
	<title>IJMS, Vol. 11, Pages 3513-3528: Human Umbilical Cord Blood Stem Cells: Rational for Use as a Neuroprotectant in Ischemic Brain Disease</title>
	<link>http://www.mdpi.com/1422-0067/11/9/3513/</link>
	<description>The use of stem cells for reparative medicine was first proposed more than three decades ago. Hematopoietic stem cells from bone marrow, peripheral blood and human umbilical cord blood (CB) have gained major use for treatment of hematological indications. CB, however, is also a source of cells capable of differentiating into various non-hematopoietic cell types, including neural cells. Several animal model reports have shown that CB cells may be used for treatment of neurological injuries. This review summarizes the information available on the origin of CB-derived neuronal cells and the mechanisms proposed to explain their action. The potential use of stem/progenitor cells for treatment of ischemic brain injuries is discussed. Issues that remain to be resolved at the present stage of preclinical trials are addressed.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/9/3513/</guid>
	<pubDate>Tue, 21 Sep 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-09-21</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>9</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>3513</prism:startingPage>
		<prism:endingPage>3528</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Human Umbilical Cord Blood Stem Cells: Rational for Use as a Neuroprotectant in Ischemic Brain Disease</dc:title>
	<dc:date>2010-09-21</dc:date>
	<dc:identifier>doi: 10.3390/ijms11093513</dc:identifier>
		<dc:creator>Hadar Arien-Zakay</dc:creator>
		<dc:creator>Shimon Lecht</dc:creator>
		<dc:creator>Arnon Nagler</dc:creator>
		<dc:creator>Philip Lazarovici</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/8/2901/">
	<title>IJMS, Vol. 11, Pages 2901-2909: Hypoxic and Highly Angiogenic Non-Tumor Tissues Surrounding Hepatocellular Carcinoma: The ‘Niche’ of Endothelial Progenitor Cells</title>
	<link>http://www.mdpi.com/1422-0067/11/8/2901/</link>
	<description>Our previous investigations showed that mobilized endothelial progenitor cells (EPCs) are enriched in non-tumor tissues (NT) surrounding hepatocellular carcinoma (HCC), compared to in tumor tissues (TT). This particular recruitment of EPCs is worth investigating further. The mobilization, recruitment, homing, and incorporation of EPCs into tumors require the participation of multiple factors, including angiogenic factors, adherent molecules, endothelial cells, hypoxic environment, etc. Therefore, we hypothesized that NT might be a hypoxic and highly angiogenic area, into which many more EPCs are recruited and homed. In the last three years, we evaluated the hypoxic condition, angiogenic factors and angiogenic index using frozen tissues or tissue microarrays from 105 patients who had undergone hepatectomy for HCC, and here we review our results and the studies of others. All results showed the expression of Hypoxia-inducible factor-1α was higher in NT than in TT. The expression of VEGFA, bFGF, TGF-β, MCP-1, MMP-9, TIMP-2, and endostatin in NT was significantly higher than in normal liver and TT. Meanwhile, the expression of CD105—the surface marker of activated endothelial cells—was also higher in NT than in TT at the protein and mRNA levels. These investigations showed that NT is a hypoxic and highly angiogenic area, which may be the ‘niche’ of EPCs. The particular background in HCC may be related to liver cirrhosis. Therefore, non-tumor tissues surrounding HCC may be the ‘niche’ of endothelial progenitor cells.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/8/2901/</guid>
	<pubDate>Mon, 09 Aug 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-08-09</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2901</prism:startingPage>
		<prism:endingPage>2909</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Hypoxic and Highly Angiogenic Non-Tumor Tissues Surrounding Hepatocellular Carcinoma: The ‘Niche’ of Endothelial Progenitor Cells</dc:title>
	<dc:date>2010-08-09</dc:date>
	<dc:identifier>doi: 10.3390/ijms11082901</dc:identifier>
		<dc:creator>De-Cai Yu</dc:creator>
		<dc:creator>Jun Chen</dc:creator>
		<dc:creator>Yi-Tao Ding</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/8/2875/">
	<title>IJMS, Vol. 11, Pages 2875-2900: The Yin and Yang of VEGF and PEDF: Multifaceted Neurotrophic Factors and Their Potential in the Treatment of Parkinson’s Disease</title>
	<link>http://www.mdpi.com/1422-0067/11/8/2875/</link>
	<description>Over the last few decades, vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) have emerged as multifaceted players in not only the pathogenesis, but potential treatment, of numerous diseases. They activate diverse intracellular signaling cascades known to have extensive crosstalk, and have been best studied for their effects in cardiology and cancer biology. Recent work with the two factors indicates that the activity of one growth factor is often directly related to the action of the other. Their respective neuroprotective effects, in particular, raise important questions regarding the treatment of neurodegenerative disorders, including Parkinson’s disease.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/8/2875/</guid>
	<pubDate>Thu, 05 Aug 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-08-05</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>8</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2875</prism:startingPage>
		<prism:endingPage>2900</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>The Yin and Yang of VEGF and PEDF: Multifaceted Neurotrophic Factors and Their Potential in the Treatment of Parkinson’s Disease</dc:title>
	<dc:date>2010-08-05</dc:date>
	<dc:identifier>doi: 10.3390/ijms11082875</dc:identifier>
		<dc:creator>Torsten Falk</dc:creator>
		<dc:creator>Robert T. Gonzalez</dc:creator>
		<dc:creator>Scott J. Sherman</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/7/2658/">
	<title>IJMS, Vol. 11, Pages 2658-2669: The Effect of Treadmill Training Pre-Exercise on Glutamate Receptor Expression in Rats after Cerebral Ischemia</title>
	<link>http://www.mdpi.com/1422-0067/11/7/2658/</link>
	<description>Physical exercise has been demonstrated to be neuroprotective in both clinical and laboratory settings. However, the exact mechanism underlying this effect is unclear. Our study aimed to investigate whether pre-ischemic treadmill training could serve as a form of ischemic preconditioning in a rat model undergoing middle cerebral artery occlusion (MCAO). Thirty-six rats were divided into three groups: a sham control group, a non-exercise with operation group and an exercise with operation group. After treadmill training, ischemia was induced by occluding the MCA for 2 h, followed by reperfusion. Half of the rats in each group were sacrificed for mRNA detection of mGluR5 and NR2B 80 min after occlusion. The remaining animals were evaluated for neurological deficits by behavioral scoring and then decapitated to assess the infarct volume. The mRNA expression of mGluR5 and NR2B was detected by real-time PCR. The results suggest that pre-ischemic treadmill training may induce brain ischemic tolerance by reducing the mRNA levels of mGluR5 and NR2B, and thus, the results indicate that physical exercise might be an effective method to establish ischemic preconditioning.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/7/2658/</guid>
	<pubDate>Wed, 07 Jul 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-07-07</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>7</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>2658</prism:startingPage>
		<prism:endingPage>2669</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>The Effect of Treadmill Training Pre-Exercise on Glutamate Receptor Expression in Rats after Cerebral Ischemia</dc:title>
	<dc:date>2010-07-07</dc:date>
	<dc:identifier>doi: 10.3390/ijms11072658</dc:identifier>
		<dc:creator> Zhang</dc:creator>
		<dc:creator> Jia</dc:creator>
		<dc:creator> Wu</dc:creator>
		<dc:creator> Hu</dc:creator>
		<dc:creator> Wang</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/6/2306/">
	<title>IJMS, Vol. 11, Pages 2306-2321: An Antiapoptotic Neuroprotective Role for Neuroglobin</title>
	<link>http://www.mdpi.com/1422-0067/11/6/2306/</link>
	<description>Cell death associated with mitochondrial dysfunction is common in acute neurological disorders and in neurodegenerative diseases. Neuronal apoptosis is regulated by multiple proteins, including neuroglobin, a small heme protein of ancient origin. Neuroglobin is found in high concentration in some neurons, and its high expression has been shown to promote survival of neurons in vitro and to protect brain from damage by both stroke and Alzheimer’s disease in vivo. Early studies suggested this protective role might arise from the protein’s capacity to bind oxygen or react with nitric oxide. Recent data, however, suggests that neither of these functions is likely to be of physiological significance. Other studies have shown that neuroglobin reacts very rapidly with cytochrome c released from mitochondria during cell death, thus interfering with the intrinsic pathway of apoptosis. Systems level computational modelling suggests that the physiological role of neuroglobin is to reset the trigger level for the post-mitochondrial execution of apoptosis. An understanding of the mechanism of action of neuroglobin might thus provide a rational basis for the design of new drug targets for inhibiting excessive neuronal cell death.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/6/2306/</guid>
	<pubDate>Thu, 27 May 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-05-27</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2306</prism:startingPage>
		<prism:endingPage>2321</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>An Antiapoptotic Neuroprotective Role for Neuroglobin</dc:title>
	<dc:date>2010-05-27</dc:date>
	<dc:identifier>doi: 10.3390/ijms11062306</dc:identifier>
		<dc:creator> Brittain</dc:creator>
		<dc:creator> Skommer</dc:creator>
		<dc:creator> Raychaudhuri</dc:creator>
		<dc:creator> Birch</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/6/2291/">
	<title>IJMS, Vol. 11, Pages 2291-2305: Neuritogenic and Neuroprotective Properties of Peptide Agonists of the Fibroblast Growth Factor Receptor</title>
	<link>http://www.mdpi.com/1422-0067/11/6/2291/</link>
	<description>Fibroblast growth factor receptors (FGFRs) interact with their cognate ligands, FGFs, and with a number of cell adhesion molecules (CAMs), such as the neural cell adhesion molecule (NCAM), mediating a wide range of events during the development and maintenance of the nervous system. Determination of protein structure, in silico modeling and biological studies have recently resulted in the identification of FGFR binding peptides derived from various FGFs and NCAM mimicking the effects of these molecules with regard to their neuritogenic and neuroprotective properties. This review focuses on recently developed functional peptide agonists of FGFR with possible therapeutic potential.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/6/2291/</guid>
	<pubDate>Wed, 26 May 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-05-26</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>6</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>2291</prism:startingPage>
		<prism:endingPage>2305</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Neuritogenic and Neuroprotective Properties of Peptide Agonists of the Fibroblast Growth Factor Receptor</dc:title>
	<dc:date>2010-05-26</dc:date>
	<dc:identifier>doi: 10.3390/ijms11062291</dc:identifier>
		<dc:creator> Li</dc:creator>
		<dc:creator> Bock</dc:creator>
		<dc:creator> Berezin</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/5/2109/">
	<title>IJMS, Vol. 11, Pages 2109-2117: Lutein Protects RGC-5 Cells Against Hypoxia and Oxidative Stress</title>
	<link>http://www.mdpi.com/1422-0067/11/5/2109/</link>
	<description>Retinal ischemia and oxidative stress lead to neuronal death in many ocular pathologies. Recently, we found that lutein, an oxy-carotenoid, protected the inner retina from ischemia/reperfusion injury. However, it is uncertain whether lutein directly protects retinal ganglion cells (RGCs). Here, an in vitro model of hypoxia and oxidative stress was used to further investigate the neuroprotective role of lutein in RGCs. Cobalt chloride (CoCl2)and hydrogen peroxide (H2O2) were added to a transformed RGC cell line, RGC-5, to induce chemical hypoxia and oxidative stress, respectively. Either lutein or vehicle was added to cultured cells. A higher cell count was observed in the lutein-treated cells compared with the vehicle-treated cells. Our data from this in vitro model revealed that lutein might protect RGC-5 cells from damage when exposed to either CoCl2-induced chemical hypoxia or H2O2-induced oxidative stress. These results suggest that lutein may play a role as a neuroprotectant.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/5/2109/</guid>
	<pubDate>Tue, 11 May 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-05-11</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>2109</prism:startingPage>
		<prism:endingPage>2117</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Lutein Protects RGC-5 Cells Against Hypoxia and Oxidative Stress</dc:title>
	<dc:date>2010-05-11</dc:date>
	<dc:identifier>doi: 10.3390/ijms11052109</dc:identifier>
		<dc:creator> Li</dc:creator>
		<dc:creator> Lo</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/5/2039/">
	<title>IJMS, Vol. 11, Pages 2039-2055: Stem Cell-Based Neuroprotective and Neurorestorative Strategies</title>
	<link>http://www.mdpi.com/1422-0067/11/5/2039/</link>
	<description>Stem cells, a special subset of cells derived from embryo or adult tissues, are known to present the characteristics of self-renewal, multiple lineages of differentiation, high plastic capability, and long-term maintenance. Recent reports have further suggested that neural stem cells (NSCs) derived from the adult hippocampal and subventricular regions possess the utilizing potential to develop the transplantation strategies and to screen the candidate agents for neurogenesis, neuroprotection, and neuroplasticity in neurodegenerative diseases. In this article, we review the roles of NSCs and other stem cells in neuroprotective and neurorestorative therapies for neurological and psychiatric diseases. We show the evidences that NSCs play the key roles involved in the pathogenesis of several neurodegenerative disorders, including depression, stroke and Parkinson’s disease. Moreover, the potential and possible utilities of induced pluripotent stem cells (iPS), reprogramming from adult fibroblasts with ectopic expression of four embryonic genes, are also reviewed and further discussed. An understanding of the biophysiology of stem cells could help us elucidate the pathogenicity and develop new treatments for neurodegenerative disorders. In contrast to cell transplantation therapies, the application of stem cells can further provide a platform for drug discovery and small molecular testing, including Chinese herbal medicines. In addition, the high-throughput stem cell-based systems can be used to elucidate the mechanisms of neuroprotective candidates in translation medical research for neurodegenerative diseases.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/5/2039/</guid>
	<pubDate>Wed, 05 May 2010 00:00:00 CEST</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-05-05</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>5</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>2039</prism:startingPage>
		<prism:endingPage>2055</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Stem Cell-Based Neuroprotective and Neurorestorative Strategies</dc:title>
	<dc:date>2010-05-05</dc:date>
	<dc:identifier>doi: 10.3390/ijms11052039</dc:identifier>
		<dc:creator> Hung</dc:creator>
		<dc:creator> Liou</dc:creator>
		<dc:creator> Lu</dc:creator>
		<dc:creator> Tseng</dc:creator>
		<dc:creator> Kao</dc:creator>
		<dc:creator> Chen</dc:creator>
		<dc:creator> Chiou</dc:creator>
		<dc:creator> Chang</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/4/1253/">
	<title>IJMS, Vol. 11, Pages 1253-1268: A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study</title>
	<link>http://www.mdpi.com/1422-0067/11/4/1253/</link>
	<description>We examined the neuro/axono-protective potential of a novel poly (ADP-ribose) polymerase (PARP) inhibitor L-2286 in a rat impact acceleration brain injury model. Male Wistar rats (n = 70) weighing 300-350 grams were used to determine the most effective intracerebroventricular (i.c.v.) dose of L-2286 administered 30 min after injury, and to test the neuroprotective effect at two time points (immediately, and 30 min after injury). The neuroprotective effect of L-2286 was tested using immunohistochemical (amyloid precursor protein and mid-sized mouse anti-neurofilament clone RMO-14.9 antibody) and behavioral tests (beam-balance, open-field and elevated plus maze). At both time-points, a 100 µg/rat dose of i.c.v. L-2286 significantly (p &lt; 0.05) reduced the density of damaged axons in the corticospinal tract and medial longitudinal fascicle compared to controls. In the behavioral tests, treatment 30 min post-injury improved motor function, while the level of anxiety was reduced in both treatment protocols.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/4/1253/</guid>
	<pubDate>Fri, 26 Mar 2010 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-03-26</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>4</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>1253</prism:startingPage>
		<prism:endingPage>1268</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>A Novel PARP Inhibitor L-2286 in a Rat Model of Impact Acceleration Head Injury: An Immunohistochemical and Behavioral Study</dc:title>
	<dc:date>2010-03-26</dc:date>
	<dc:identifier>doi: 10.3390/ijms11041253</dc:identifier>
		<dc:creator> Kövesdi</dc:creator>
		<dc:creator> Bukovics</dc:creator>
		<dc:creator> Besson</dc:creator>
		<dc:creator> Nyirádi</dc:creator>
		<dc:creator> Lückl</dc:creator>
		<dc:creator> Pál</dc:creator>
		<dc:creator> Sümegi</dc:creator>
		<dc:creator> Dóczi</dc:creator>
		<dc:creator> Hernádi</dc:creator>
		<dc:creator> Büki</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/2/544/">
	<title>IJMS, Vol. 11, Pages 544-561: Novel Neuroprotective Strategies in Ischemic Retinal Lesions</title>
	<link>http://www.mdpi.com/1422-0067/11/2/544/</link>
	<description>Retinal ischemia can be effectively modeled by permanent bilateral common carotid artery occlusion, which leads to chronic hypoperfusion-induced degeneration in the entire rat retina. The complex pathways leading to retinal cell death offer a complex approach of neuroprotective strategies. In the present review we summarize recent findings with different neuroprotective candidate molecules. We describe the protective effects of intravitreal treatment with: (i) urocortin 2; (ii) a mitochondrial ATP-sensitive K+ channel opener, diazoxide; (iii) a neurotrophic factor, pituitary adenylate cyclase activating polypeptide; and (iv) a novel poly(ADP-ribose) polymerase inhibitor (HO3089). The retinoprotective effects are demonstrated with morphological description and effects on apoptotic pathways using molecular biological techniques.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/2/544/</guid>
	<pubDate>Wed, 03 Feb 2010 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-02-03</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>2</prism:number>
	<prism:section>Review</prism:section>
	<prism:startingPage>544</prism:startingPage>
		<prism:endingPage>561</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Novel Neuroprotective Strategies in Ischemic Retinal Lesions</dc:title>
	<dc:date>2010-02-03</dc:date>
	<dc:identifier>doi: 10.3390/ijms11020544</dc:identifier>
		<dc:creator>Krisztina Szabadfi</dc:creator>
		<dc:creator>Laszlo Mester</dc:creator>
		<dc:creator>Dora Reglodi</dc:creator>
		<dc:creator>Peter Kiss</dc:creator>
		<dc:creator>Norbert Babai</dc:creator>
		<dc:creator>Boglarka Racz</dc:creator>
		<dc:creator>Krisztina Kovacs</dc:creator>
		<dc:creator>Aliz Szabo</dc:creator>
		<dc:creator>Andrea Tamas</dc:creator>
		<dc:creator>Robert Gabriel</dc:creator>
		<dc:creator>Tamas Atlasz</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>
	<item rdf:about="http://www.mdpi.com/1422-0067/11/1/312/">
	<title>IJMS, Vol. 11, Pages 312-328: Melatonin and Structurally-Related Compounds Protect Synaptosomal Membranes from Free Radical Damage</title>
	<link>http://www.mdpi.com/1422-0067/11/1/312/</link>
	<description>Since biological membranes are composed of lipids and proteins we tested the in vitro antioxidant properties of several indoleamines from the tryptophan metabolic pathway in the pineal gland against oxidative damage to lipids and proteins of synaptosomes isolated from the rat brain. Free radicals were generated by incubation with 0.1 mM FeCl3, and 0.1 mM ascorbic acid. Levels of malondialdehyde (MDA) plus 4-hydroxyalkenal (4-HDA), and carbonyl content in the proteins were measured as indices of oxidative damage to lipids and proteins, respectively. Pinoline was the most powerful antioxidant evaluated, with melatonin, N-acetylserotonin, 5-hydroxytryptophan, 5-methoxytryptamine, 5-methoxytryptophol, and tryptoline also acting as antioxidants.</description>
	
	<guid>http://www.mdpi.com/1422-0067/11/1/312/</guid>
	<pubDate>Thu, 21 Jan 2010 00:00:00 CET</pubDate>
	
	<prism:publicationName>International Journal of Molecular Sciences</prism:publicationName>
	<prism:publicationDate>2010-01-21</prism:publicationDate>
	<prism:volume>11</prism:volume>
	<prism:number>1</prism:number>
	<prism:section>Article</prism:section>
	<prism:startingPage>312</prism:startingPage>
		<prism:endingPage>328</prism:endingPage>
		<prism:issn>1422-0067</prism:issn>
	
	<dc:title>Melatonin and Structurally-Related Compounds Protect Synaptosomal Membranes from Free Radical Damage</dc:title>
	<dc:date>2010-01-21</dc:date>
	<dc:identifier>doi: 10.3390/ijms11010312</dc:identifier>
		<dc:creator>Sergio Millán-Plano</dc:creator>
		<dc:creator>Eduardo Piedrafita</dc:creator>
		<dc:creator>Francisco J. Miana-Mena</dc:creator>
		<dc:creator>Lorena Fuentes-Broto</dc:creator>
		<dc:creator>Enrique Martínez-Ballarín</dc:creator>
		<dc:creator>Laura López-Pingarrón</dc:creator>
		<dc:creator>María A. Sáenz</dc:creator>
		<dc:creator>Joaquín J. García</dc:creator>
	
	<cc:license rdf:resource="http://creativecommons.org/licenses/by/3.0/" />
</item>


<cc:License rdf:about="http://creativecommons.org/licenses/by/3.0/">
	<cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
	<cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
	<cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
</cc:License>

</rdf:RDF>
